Co-expression of CD56 and CD30 in lymphomas with primary presentation in the skin: clinicopathologic, immunohistochemical and molecular analyses of seven cases
Natkunam, Y., Warnke, R. A., Haghighi, B., Su, L. D., Le Boit, P. E., Kim, Y. H., & Kohler, S. (2000). Co-expression of CD56 and CD30 in lymphomas with primary presentation in the skin: clinicopathologic, immunohistochemical and molecular analyses of seven cases. JOURNAL OF CUTANEOUS PATHOLOGY, 27(8), 392–99.

Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides
de Coninck, E. C., Kim, Y. H., Varghese, A., & Hoppe, R. T. (2001). Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. JOURNAL OF CLINICAL ONCOLOGY, 19(3), 779–84.

Natural killer/natural killer-like T-Cell lymphoma, CD56+, presenting in the skin: An increasingly recognized entity with an aggressive course
Mraz-Gernhard, S., Natkunam, Y., Hoppe, R. T., Leboit, P., Kohler, S., & Kim, Y. H. (2001). Natural killer/natural killer-like T-Cell lymphoma, CD56+, presenting in the skin: An increasingly recognized entity with an aggressive course. JOURNAL OF CLINICAL ONCOLOGY, 19(8), 2179–88.

Interstitial mycosis fungoides, a variant of mycosis fungoides resembling granuloma annulare and inflammatory morphea
Su, L. D., Kim, Y. H., LeBoit, P. E., Swetter, S. M., & Kohler, S. (2002). Interstitial mycosis fungoides, a variant of mycosis fungoides resembling granuloma annulare and inflammatory morphea. JOURNAL OF CUTANEOUS PATHOLOGY, 29(3), 135–41.

Large atypical cells of lymphomatoid papulosis are CD56-negative: a study of 18 cases
Harvell, J. D., Vaseghi, M., Natkunam, Y., Kohler, S., & Kim, Y. (2002). Large atypical cells of lymphomatoid papulosis are CD56-negative: a study of 18 cases. JOURNAL OF CUTANEOUS PATHOLOGY, 29(2), 88–92.

Topical nitrogen mustard in the management of mycosis fungoides - Update of the Stanford experience
Kim, Y. H., Martinez, G., Varghese, A., & Hoppe, R. T. (2003). Topical nitrogen mustard in the management of mycosis fungoides - Update of the Stanford experience. ARCHIVES OF DERMATOLOGY, 139(2), 165–73.

Gene expression profiles of cutaneous B cell lymphoma
Storz, M. N., van de Rijn, M., Kim, Y. H., Mraz-Gernhard, S., Hoppe, R. T., & Kohler, S. (2003). Gene expression profiles of cutaneous B cell lymphoma. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 120(5), 865–70.

Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome - Clinical prognostic factors and risk for disease progression
Kim, Y. H., Liu, H. L., Mraz-Gernhard, S., Varghese, A., & Hoppe, R. T. (2003). Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome - Clinical prognostic factors and risk for disease progression. ARCHIVES OF DERMATOLOGY, 139(7), 857–66.

RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA PHENOTYPE IS PRESERVED IN XENOGRAFTS USING SCID MICE - DEVELOPMENT OF AN EXPERIMENTAL INVIVO MODEL
Kim, Y. H., Woodley, D. T., WYNN, K. C., GIOMI, W., & BAUER, E. A. (1992). RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA PHENOTYPE IS PRESERVED IN XENOGRAFTS USING SCID MICE - DEVELOPMENT OF AN EXPERIMENTAL INVIVO MODEL. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 98(2), 191–97.

A DOUBLE-BLIND COMPARISON OF ADHESIVE BANDAGES WITH THE USE OF UNIFORM SUCTION BLISTER WOUNDS
Woodley, D. T., & Kim, Y. H. (1992). A DOUBLE-BLIND COMPARISON OF ADHESIVE BANDAGES WITH THE USE OF UNIFORM SUCTION BLISTER WOUNDS. ARCHIVES OF DERMATOLOGY, 128(10), 1354–57.

CD30(+) cutaneous lymphoproliferative disorders: The Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma
Liu, H. L., Hoppe, R. T., Kohler, S., Harvell, J. D., Reddy, S., & Kim, Y. H. (2003). CD30(+) cutaneous lymphoproliferative disorders: The Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 49(6), 1049–58.

Management with topical nitrogen mustard in mycosis fungoides.
Kim, Y. H. (2003). Management with topical nitrogen mustard in mycosis fungoides. Dermatologic Therapy, 16(4), 288–98.

Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patients
Beynet, D. P., Wee, S. A., Horwitz, S. S., Kohler, S., Horning, S., Hoppe, R., & Kim, Y. H. (2004). Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patients. ARCHIVES OF DERMATOLOGY, 140(9), 1140–46.

Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study
Sundram, U., Kim, Y., Mraz-Gernhard, S., Hoppe, R., Natkunam, Y., & Kohler, S. (2005). Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study. JOURNAL OF CUTANEOUS PATHOLOGY, 32(3), 227–34.

Staging accuracy in mycosis fungoides and Sezary syndrome using integrated positron emission tomography and computed tomography
Tsai, E. Y., Taur, A., Espinosa, L., Quon, A., Johnson, D., Dick, S., … Kim, Y. H. (2006). Staging accuracy in mycosis fungoides and Sezary syndrome using integrated positron emission tomography and computed tomography. ARCHIVES OF DERMATOLOGY, 142(5), 577–84.

Cutaneous involvement by angioimmunoblastic T-cell lymphoma: a unique histologic presentation, mimicking an infectious etiology
Jayaraman, A. G., Cassarino, D., Advani, R., Kim, Y. H., Tsai, E., & Kohler, S. (2006). Cutaneous involvement by angioimmunoblastic T-cell lymphoma: a unique histologic presentation, mimicking an infectious etiology. JOURNAL OF CUTANEOUS PATHOLOGY, 33, 6–11.

Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome - Evidence from population-based and clinical cohorts
Huang, K. P., Weinstock, M. A., Clarke, C. A., McMillan, A., Hoppe, R. T., & Kim, Y. H. (2007). Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome - Evidence from population-based and clinical cohorts. ARCHIVES OF DERMATOLOGY, 143(1), 45–50.

Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma
Kim, Y. H., Duvic, M., Obitz, E., Gniadecki, R., Iversen, L., Osterborg, A., … Knox, S. J. (2007). Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. BLOOD, 109(11), 4655–62.

TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)
Kim, Y. H., Willemze, R., Pimpinelli, N., Whittaker, S., Olsens, E. A., Ranki, A., … Hoppe, R. T. (2007). TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). BLOOD, 110(2), 479–84.

Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Olsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., … Duvic, M. (2007). Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 25(21), 3109–3115.

T-cell clonality analysis in biopsy specimens from two different skin sites shows high specificity in the diagnosis of patients with suggested mycosis fungoides
Thurber, S. E., Zhang, B., Kim, Y. H., Schrijver, I., Zehnder, J., & Kohler, S. (2007). T-cell clonality analysis in biopsy specimens from two different skin sites shows high specificity in the diagnosis of patients with suggested mycosis fungoides. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 57(5), 782–90.

Nephrogenic systemic fibrosis - Relationship to gadolinium and response to photopheresis
Richmond, H., Zwerner, J., Kim, Y., & Fiorentino, D. (2007). Nephrogenic systemic fibrosis - Relationship to gadolinium and response to photopheresis. ARCHIVES OF DERMATOLOGY, 143(8), 1025–30.

Expression of HGAL in primary cutaneous large B-cell lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphoma
Xie, X., Sundram, U., Natkunam, Y., Kohler, S., Hoppe, R. T., Kim, Y. H., … Hsi, E. D. (2008). Expression of HGAL in primary cutaneous large B-cell lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphoma. MODERN PATHOLOGY, 21(6), 653–59.

An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML
Bullinger, L., Doehner, K., Kranz, R., Stirner, C., Froeling, S., Scholl, C., … Pollack, J. R. (2008). An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. BLOOD, 111(9), 4490–95.

Clinicopathologic features and treatment outcomes in Woringer-Kolopp disease
Lee, J., Viakhireva, N., Cesca, C., Lee, P., Kohler, S., Hoppe, R. I., & Kim, Y. H. (2008). Clinicopathologic features and treatment outcomes in Woringer-Kolopp disease. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 59(4), 706–12.

Cytologic Evaluation of Lymphadenopathy Associated With Mycosis Fungoides and Sezary Syndrome Role of Immunophenotypic and Molecular Ancillary Studies
Pai, R. K., Mullins, F. M., Kim, Y. H., & Kong, C. S. (2008). Cytologic Evaluation of Lymphadenopathy Associated With Mycosis Fungoides and Sezary Syndrome Role of Immunophenotypic and Molecular Ancillary Studies. CANCER CYTOPATHOLOGY, 114(5), 323–32.

Evaluation of B-cell clonality using the BIOMED-2 PCR method effectively distinguishes cutaneous B-cell lymphoma from benign lymphoid infiltrates
Morales, A. V., Arber, D. A., Seo, K., Kohler, S., Kim, Y. H., & Sundram, U. N. (2008). Evaluation of B-cell clonality using the BIOMED-2 PCR method effectively distinguishes cutaneous B-cell lymphoma from benign lymphoid infiltrates. AMERICAN JOURNAL OF DERMATOPATHOLOGY, 30(5), 425–30.

Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab
Morales, A. V., Advani, R., Horwitz, S. M., Riaz, N., Reddy, S., Hoppe, R. T., & Kim, Y. H. (2008). Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 59(6), 953–57.

Low Stage Follicular Lymphoma: Biologic and Clinical Characterization According to Nodal or Extranodal Primary Origin
Weinberg, O. K., Ma, L., Seo, K., Beck, A. H., Pai, R. K., Morales, A., … Arber, D. A. (2009). Low Stage Follicular Lymphoma: Biologic and Clinical Characterization According to Nodal or Extranodal Primary Origin. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 33(4), 591–98.

Cutaneous Peripheral T-Cell Lymphoma Associated With a Proliferation of B Cells
Mattoch, I. W., Fulton, R., Kim, Y., Hoppe, R., Warnke, R. A., & Sundram, U. N. (2009). Cutaneous Peripheral T-Cell Lymphoma Associated With a Proliferation of B Cells. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 131(6), 810–19.

Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome
Woo, D. K., Jones, C. R., Vanoli-Storz, M. N., Kohler, S., Reddy, S., Advani, R., … Kim, Y. H. (2009). Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome. ARCHIVES OF DERMATOLOGY, 145(6), 667–74.

A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sezary Syndrome
Wu, P. A., Kim, Y. H., Lavori, P. W., Hoppe, R. T., & Stockerl-Goldstein, K. E. (2009). A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sezary Syndrome. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 15(8), 982–90.

A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders
Duvic, M., Reddy, S. A., Pinter-Brown, L., Korman, N. J., Zic, J., Kennedy, D. A., … Kim, Y. H. (2009). A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders. CLINICAL CANCER RESEARCH, 15(19), 6217–6224.

Combined Use of PCR-Based TCRG and TCRB Clonality Tests on Paraffin-Embedded Skin Tissue in the Differential Diagnosis of Mycosis Fungoides and Inflammatory Dermatoses
Zhang, B., Beck, A. H., Taube, J. M., Kohler, S., Seo, K., Zwerner, J., … Zehnder, J. L. (2010). Combined Use of PCR-Based TCRG and TCRB Clonality Tests on Paraffin-Embedded Skin Tissue in the Differential Diagnosis of Mycosis Fungoides and Inflammatory Dermatoses. JOURNAL OF MOLECULAR DIAGNOSTICS, 12(3), 320–27.

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., … Levy, R. (2010). In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study. JOURNAL OF CLINICAL ONCOLOGY, 28(28), 4324–32.

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
Whittaker, S. J., Demierre, M.-F., Kim, E. J., Rook, A. H., Lerner, A., Duvic, M., … Kim, Y. H. (2010). Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 28(29), 4485–91.

Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
Kim, Y. H., Girardi, M., Duvic, M., Kuzel, T., Link, B. K., Brown, L. P., & Rook, A. H. (2010). Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 63(6), 975–83.

REVISITING LOW-DOSE TOTAL SKIN ELECTRON BEAM THERAPY IN MYCOSIS FUNGOIDES
Harrison, C., Young, J., Navi, D., Riaz, N., Lingala, B., Kim, Y., & Hoppe, R. (2011). REVISITING LOW-DOSE TOTAL SKIN ELECTRON BEAM THERAPY IN MYCOSIS FUNGOIDES. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(4), E651–E657.

The Stanford University Experience With Conventional-Dose, Total Skin Electron-Beam Therapy in the Treatment of Generalized Patch or Plaque (T2) and Tumor (T3) Mycosis Fungoides
Navi, D., Riaz, N., Levin, Y. S., Sullivan, N. C., Kim, Y. H., & Hoppe, R. T. (2011). The Stanford University Experience With Conventional-Dose, Total Skin Electron-Beam Therapy in the Treatment of Generalized Patch or Plaque (T2) and Tumor (T3) Mycosis Fungoides. ARCHIVES OF DERMATOLOGY, 147(5), 561–67.

Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
Olsen, E. A., Whittaker, S., Kim, Y. H., Duvic, M., Prince, H. M., Lessin, S. R., … Vonderheid, E. C. (2011). Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. JOURNAL OF CLINICAL ONCOLOGY, 29(18), 2598–2607.

The frequency of dual TCR-PCR clonality in granulomatous disorders
Dabiri, S., Morales, A., Ma, L., Sundram, U., Kim, Y. H., Arber, D. A., & Kim, J. (2011). The frequency of dual TCR-PCR clonality in granulomatous disorders. JOURNAL OF CUTANEOUS PATHOLOGY, 38(9), 704–9.

Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma
Querfeld, C., Kuzel, T. M., Kim, Y. H., Porcu, P., Duvic, M., Musiek, A., … Rosen, S. T. (2011). Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. LEUKEMIA & LYMPHOMA, 52(8), 1474–1480.

In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study
Kim, Y. H., Gratzinger, D., Harrison, C., Brody, J. D., Czerwinski, D. K., Ai, W. Z., … Levy, R. (2012). In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. BLOOD, 119(2), 355–63.

A Comparative Analysis of Cutaneous Marginal Zone Lymphoma and Cutaneous Chronic Lymphocytic Leukemia
Levin, C., Mirzamani, N., Zwerner, J., Kim, Y., Schwartz, E. J., & Sundram, U. (2012). A Comparative Analysis of Cutaneous Marginal Zone Lymphoma and Cutaneous Chronic Lymphocytic Leukemia. AMERICAN JOURNAL OF DERMATOPATHOLOGY, 34(1), 18–23.

The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients
Kelly-Sell, M. J., Kim, Y. H., Straus, S., Benoit, B., Harrison, C., Sutherland, K., … Rook, A. H. (2012). The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients. AMERICAN JOURNAL OF HEMATOLOGY, 87(4), 354–60.

Clonal Identity and Differences in Primary Cutaneous B-Cell Lymphoma Occurring at Different Sites or Time Points in the Same Patient
Fujiwara, M., Morales, A. V., Seo, K., Kim, Y. H., Arber, D. A., & Sundram, U. N. (2013). Clonal Identity and Differences in Primary Cutaneous B-Cell Lymphoma Occurring at Different Sites or Time Points in the Same Patient. AMERICAN JOURNAL OF DERMATOPATHOLOGY, 35(1), 11–18.

Romidepsin Is Effective in Subcutaneous Panniculitis-Like T-Cell Lymphoma
Bashey, S., Krathen, M., Abdulla, F., Sundram, U., & Kim, Y. H. (2012). Romidepsin Is Effective in Subcutaneous Panniculitis-Like T-Cell Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 30(24), E221–E225.

Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin
Kim, Y. H., Demierre, M.-F., Kim, E. J., Lerner, A., Rook, A. H., Duvic, M., … Whittaker, S. (2013). Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. LEUKEMIA & LYMPHOMA, 54(2), 284–89.

Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts
Lee, C. S., Ungewickell, A., Bhaduri, A., Qu, K., Webster, D. E., Armstrong, R., … Khavari, P. A. (2012). Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts. BLOOD, 120(16), 3288–97.

Cutaneous gamma delta T-cell Lymphomas A Spectrum of Presentations With Overlap With Other Cytotoxic Lymphomas
Guitart, J., Weisenburger, D. D., Subtil, A., Kim, E., Wood, G., Duvic, M., … Kim, Y. H. (2012). Cutaneous gamma delta T-cell Lymphomas A Spectrum of Presentations With Overlap With Other Cytotoxic Lymphomas. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 36(11), 1656–1665.

Intravascular ALK-negative Anaplastic Large Cell Lymphoma With Localized Cutaneous Involvement and an Indolent Clinical Course Toward Recognition of a Distinct Clinicopathologic Entity
Metcalf, R. A., Bashey, S., Wysong, A., Kim, J., Kim, Y. H., & Gratzinger, D. (2013). Intravascular ALK-negative Anaplastic Large Cell Lymphoma With Localized Cutaneous Involvement and an Indolent Clinical Course Toward Recognition of a Distinct Clinicopathologic Entity. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 37(4), 617–23.

H-1-NMR SPECTROSCOPY - AN APPROACH TO EVALUATION OF DISEASED SKIN INVIVO
Kim, Y. H., Orenberg, E. K., Faull, K. F., WADEJARDETZKY, N. G., & Jardetzky, O. (1989). H-1-NMR SPECTROSCOPY - AN APPROACH TO EVALUATION OF DISEASED SKIN INVIVO. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 92(2), 210–16.

REASSESSMENT OF HISTOLOGIC PARAMETERS IN THE DIAGNOSIS OF MYCOSIS-FUNGOIDES
SMOLLER, B. R., Bishop, K., Glusac, E., Kim, Y. H., & Hendrickson, M. (1995). REASSESSMENT OF HISTOLOGIC PARAMETERS IN THE DIAGNOSIS OF MYCOSIS-FUNGOIDES. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 19(12), 1423–30.

CUTANEOUS GNATHOSTOMIASIS
Crowley, J. J., & Kim, Y. H. (1995). CUTANEOUS GNATHOSTOMIASIS. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 33(5), 825–28.

PROGNOSTIC FACTORS IN ERYTHRODERMIC MYCOSIS-FUNGOIDES AND THE SEZARY-SYNDROME
Kim, Y. H., Bishop, K., Varghese, A., & Hoppe, R. T. (1995). PROGNOSTIC FACTORS IN ERYTHRODERMIC MYCOSIS-FUNGOIDES AND THE SEZARY-SYNDROME. ARCHIVES OF DERMATOLOGY, 131(9), 1003–8.

Autoimmunity to anchoring fibrils.
Kim, Y. H., & Woodley, D. T. (1994). Autoimmunity to anchoring fibrils. Advances in Dermatology, 9, 61–77.

CONSTITUTIVE ACTIVATION OF THE COLLAGENASE PROMOTER IN RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA FIBROBLASTS - ROLE OF ENDOGENOUSLY ACTIVATED AP-1
Unemori, E. N., Mauch, C., Hoeffler, W., Kim, Y., Amento, E. P., & BAUER, E. A. (1994). CONSTITUTIVE ACTIVATION OF THE COLLAGENASE PROMOTER IN RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA FIBROBLASTS - ROLE OF ENDOGENOUSLY ACTIVATED AP-1. EXPERIMENTAL CELL RESEARCH, 211(2), 212–18.

Clinical stage IA (limited patch and plaque) mycosis fungoides - A long-term outcome analysis
Kim, Y. H., Jensen, R. A., WATANABE, G. L., Varghese, A., & Hoppe, R. T. (1996). Clinical stage IA (limited patch and plaque) mycosis fungoides - A long-term outcome analysis. ARCHIVES OF DERMATOLOGY, 132(11), 1309–13.

Blastomycosis-like pyoderma in a man with AIDS
Crowley, J. J., & Kim, Y. H. (1997). Blastomycosis-like pyoderma in a man with AIDS. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 36(4), 633–34.

Histologic criteria for the diagnosis of erythrodermic mycosis fungoides and Sezary syndrome: A critical reappraisal
Kohler, S., Kim, Y. H., & SMOLLER, B. R. (1997). Histologic criteria for the diagnosis of erythrodermic mycosis fungoides and Sezary syndrome: A critical reappraisal. JOURNAL OF CUTANEOUS PATHOLOGY, 24(5), 292–97.

Mycosis fungoides in young patients: Clinical characteristics and outcome
Crowley, J. J., Nikko, A., Varghese, A., Hoppe, R. T., & Kim, Y. H. (1998). Mycosis fungoides in young patients: Clinical characteristics and outcome. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 38(5), 696–701.

Role of histology in providing prognostic information in mycosis fungoides
SMOLLER, B. R., Detwiler, S. P., Kohler, S., Hoppe, R. T., & Kim, Y. H. (1998). Role of histology in providing prognostic information in mycosis fungoides. JOURNAL OF CUTANEOUS PATHOLOGY, 25(6), 311–15.

Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides
Kim, Y. H., Chow, S., Varghese, A., & Hoppe, R. T. (1999). Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. ARCHIVES OF DERMATOLOGY, 135(1), 26–32.

Low dose pralatrexate (PDX) is active in cutaneous T-cell lymphoma: Preliminary results of a multi-center dose finding trial
Horwitz, S., Duvic, M., Kim, Y., Chance, L., Myskowski, P., Talpur, R., … O'Connor, O. (2008). Low dose pralatrexate (PDX) is active in cutaneous T-cell lymphoma: Preliminary results of a multi-center dose finding trial. Presented at the 10th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND: OXFORD UNIV PRESS.

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma
Horwitz, S. M., Kim, Y. H., Foss, F., Zain, J. M., Myskowski, P. L., Lechowicz, M. J., … Duvic, M. (2012). Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. BLOOD, 119(18), 4115–22.

JUNCTIONAL EPIDERMOLYSIS-BULLOSA (JEB) KERATINOCYTES FAIL TO SECRETE HEMIDESMOSOME (HD)-ASSOCIATED MATRIX-ELEMENTS AND DEMONSTRATE ENHANCED LOCOMOTION
Chen, J. D., LANGHOFER, M., Iwasaki, T., Kim, Y. H., Jones, J. C. R., Krueger, J. G., … Woodley, D. T. (1993). JUNCTIONAL EPIDERMOLYSIS-BULLOSA (JEB) KERATINOCYTES FAIL TO SECRETE HEMIDESMOSOME (HD)-ASSOCIATED MATRIX-ELEMENTS AND DEMONSTRATE ENHANCED LOCOMOTION. CLINICAL RESEARCH, 41(2), A408–A408.

JUNCTIONAL EPIDERMOLYSIS-BULLOSA (JEB) KERATINOCYTES FAIL TO SECRETE HEMIDESMOSOME (HD)-ASSOCIATED MATRIX-ELEMENTS AND DEMONSTRATE ENHANCED LOCOMOTION
Chen, J. D., LANGHOFER, M., Iwasaki, T., Kim, Y. H., Jones, J. C. R., Krueger, J. G., … Woodley, D. T. (1993). JUNCTIONAL EPIDERMOLYSIS-BULLOSA (JEB) KERATINOCYTES FAIL TO SECRETE HEMIDESMOSOME (HD)-ASSOCIATED MATRIX-ELEMENTS AND DEMONSTRATE ENHANCED LOCOMOTION. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 100(4), 517–17.

The morphologic and immunohistochemical overlap between cutaneous marginal zone lymphoma and cutaneous chronic lymphocytic leukemia
Levin, C., Mizramani, N., Zwerner, J., Kim, Y., & Sundram, U. (2009). The morphologic and immunohistochemical overlap between cutaneous marginal zone lymphoma and cutaneous chronic lymphocytic leukemia. Presented at the 69th Annual Meeting of the Society-of-Investigative-Dermatology, MONTREAL,CANADA: NATURE PUBLISHING GROUP.

Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study.
Horwitz, S. M., Kim, Y. H., Foss, F. M., Zain, J. M., Myskowski, P., Lechowicz, M. J., … Duvic, M. (2010). Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study. BLOOD. ORLANDO,FL,FL: AMER SOC HEMATOLOGY.

Transcriptome sequencing in Sezary Syndrome identifies novel Sezary cell-associated transcripts
Lee, C., Ungewickell, A., Bhaduri, A., Qu, K., Webster, D., Armstrong, R., … Khavari, P. A. (2012). Transcriptome sequencing in Sezary Syndrome identifies novel Sezary cell-associated transcripts. Presented at the 75th Annual Meeting of the Society-for-Investigative-Dermatology, RALEIGH,NC,NC,NC,NC,NC,NC,NC,NC,NC: NATURE PUBLISHING GROUP.

Phase II preliminary results suggest SGN-30 (Anti-CD30 monoclonal antibody) is active and well-tolerated in patients with cutaneous anaplastic large cell lymphoma
Duvic, M., Kunishige, J., Kim, Y., Reddy, S., Forero-Torres, A., Pinter-Brown, L., … Barton, J. (2006). Phase II preliminary results suggest SGN-30 (Anti-CD30 monoclonal antibody) is active and well-tolerated in patients with cutaneous anaplastic large cell lymphoma. Presented at the 67th Annual Meeting of the Society-for-Investigative-Dermatology, PHILADELPHIA,PA: NATURE PUBLISHING GROUP.

Phase II preliminary results of SGN-30 (anti-CD30 mAb) in patients with CD30+lymphoproliferative disorders.
Duvic, M., Kim, Y., Reddy, S., Forero-Torres, A., Pinter-Brown, L. C., Rarick, M. U., … Sievers, E. (2006). Phase II preliminary results of SGN-30 (anti-CD30 mAb) in patients with CD30+lymphoproliferative disorders. BLOOD, 108(11), 773A–773A.

Preliminary report on a phase I/II study of intraturnoral injection of PF-3512676 (CpG 7909), a TLR9 agonist, combined with radiation in recurrent low-grade lymphomas.
Ai, W. Y. Z., Kim, Y., Hoppe, R. T., Shah, S., Horning, S. J., Tibshirani, R., & Levy, R. (2006). Preliminary report on a phase I/II study of intraturnoral injection of PF-3512676 (CpG 7909), a TLR9 agonist, combined with radiation in recurrent low-grade lymphomas. BLOOD, 108(11), 767A–768A.

Novel in situ vaccination with intratumoral injection of CpG 7909, a TLR 9 agonist, combined with radiation in mycosis fungoides and primary cutaneous B-cell lymphoma
Morales, A. V., Hoppe, R., Shah, S., Levy, R., & Kim, Y. (2007). Novel in situ vaccination with intratumoral injection of CpG 7909, a TLR 9 agonist, combined with radiation in mycosis fungoides and primary cutaneous B-cell lymphoma. Presented at the 68th Annual Meeting of the Society-for-Investigative-Dermatology, LOS ANGELES,CA,CA: NATURE PUBLISHING GROUP.

In Situ Vaccination with TLR9 Agonist Combined with Local Radiation In Mycosis Fungoides: Analysis of Phase I/II Study
Kim, Y. H., Gratzinger, D., Harrison, C., Brody, J., Czerwinski, D., Xing, L., … Levy, R. (2010). In Situ Vaccination with TLR9 Agonist Combined with Local Radiation In Mycosis Fungoides: Analysis of Phase I/II Study. BLOOD. ORLANDO,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL: AMER SOC HEMATOLOGY.

Non-Hodgkin's Lymphomas
Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Byrd, J. C., Czuczman, M. S., … Yunus, F. (2010). Non-Hodgkin's Lymphomas. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 8(3), 288–334.

BIOLOGIC CHARACTERISTICS OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA (RDEB) KERATINOCYTES
Kim, Y. H., Kim, J. P., Chen, J. D., Iwasaki, T., Hernandez, G., SARAF, P., … Woodley, D. T. (1993). BIOLOGIC CHARACTERISTICS OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA (RDEB) KERATINOCYTES. JOURNAL OF INVESTIGATIVE DERMATOLOGY. NATURE PUBLISHING GROUP.

BIOLOGIC CHARACTERISTICS OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA (RDEB) KERATINOCYTES
Kim, Y. H., Kim, J. P., Chen, J. D., Iwasaki, T., Hernandez, G., SARAF, P., … Woodley, D. T. (1993). BIOLOGIC CHARACTERISTICS OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA (RDEB) KERATINOCYTES. CLINICAL RESEARCH. SLACK INC.

T-Cell Receptor PCR from Separate Biopsies Distinguishes Granulomatous Dermatitis from Granulomatous Mycosis Fungoides
Dabiri, S., Arber, D. A., Kim, Y. H., Sundram, U. N., & Kim, J. (2010). T-Cell Receptor PCR from Separate Biopsies Distinguishes Granulomatous Dermatitis from Granulomatous Mycosis Fungoides. Presented at the 99th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, WASHINGTON,DC,DC,DC,DC: NATURE PUBLISHING GROUP.

REASSESSMENT OF LYMPHOCYTE IMMUNOPHENOTYPING IN THE DIAGNOSIS OF PATCH AND PLAQUE STAGE LESIONS OF MYCOSIS-FUNGOIDES
SMOLLER, B. R., Bishop, K., Glusac, E. J., Kim, Y. H., Bhargava, V., & Warnke, R. A. (1995). REASSESSMENT OF LYMPHOCYTE IMMUNOPHENOTYPING IN THE DIAGNOSIS OF PATCH AND PLAQUE STAGE LESIONS OF MYCOSIS-FUNGOIDES. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 3(1), 32–36.

LYMPHOCYTE ANTIGEN ABNORMALITIES IN INFLAMMATORY DERMATOSES
SMOLLER, B. R., Bishop, K., Glusac, E. J., Bhargava, V., Kim, Y. H., & Warnke, R. A. (1995). LYMPHOCYTE ANTIGEN ABNORMALITIES IN INFLAMMATORY DERMATOSES. APPLIED IMMUNOHISTOCHEMISTRY, 3(2), 127–131.

Romidepsin (depsipeptide) induces clinically significant responses in treatment-refractory CTCL: An International, Multicenter study
Kim, Y. H., Reddy, S., Kim, E. J., Rook, A. H., Lerner, A., Demierre, M., … Prentice, A. G. (2007). Romidepsin (depsipeptide) induces clinically significant responses in treatment-refractory CTCL: An International, Multicenter study. BLOOD, 110(11), 44A–44A.

International trial confirms romidpesin efficacy in refractory CTCL patients
Prentice, A., Whittaker, S., Kim, Y., Kim, E., LERNER, A., Duvic, M., … McCulloch, W. (2008). International trial confirms romidpesin efficacy in refractory CTCL patients. Presented at the 10th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND: OXFORD UNIV PRESS.

Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study
Kim, Y., Whittaker, S., Demierre, M. F., Rook, A. H., Lerner, A., Duvic, M., … Prentice, A. G. (2008). Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study. BLOOD, 112(11), 103–104.

Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement
Kim, Y. H., Demierre, M.-F., Kim, E. J., Rook, A. H., Lerner, A., Duvic, M., … Whittaker, S. (2009). Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement. BLOOD, 114(22), 1050–1050.

Romidepsin has activity in refractory ctcl: an international multicenter study
Whittaker, S., Scarisbrick, J., Kim, Y., Reddy, S., Kim, E., Rook, A., … Prentice, A. (2008). Romidepsin has activity in refractory ctcl: an international multicenter study. Presented at the International Investigative Dermatology Meeting, KYOTO,JAPAN: NATURE PUBLISHING GROUP.

The Stanford experience with utilizing the new WHO classification of cutaneous lymphomas for cutaneous B cell lymphoma
Reddy, S., Kohler, S., Horwitz, S., Sutherland, K., Hoppe, R. T., & Kim, Y. H. (2006). The Stanford experience with utilizing the new WHO classification of cutaneous lymphomas for cutaneous B cell lymphoma. Presented at the 67th Annual Meeting of the Society-for-Investigative-Dermatology, PHILADELPHIA,PA,PA: NATURE PUBLISHING GROUP.

Superior clinical outcome for patients receiving allogeneic over autologous stem cell transplant in mycosis fungoides and Sezary syndrome
Wu, P. A., Stockerl-Goldstein, K., Reddy, S. A., Hoppe, R. T., & Kim, Y. H. (2006). Superior clinical outcome for patients receiving allogeneic over autologous stem cell transplant in mycosis fungoides and Sezary syndrome. Presented at the 67th Annual Meeting of the Society-for-Investigative-Dermatology, PHILADELPHIA,PA,PA,PA: NATURE PUBLISHING GROUP.

Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression
Krathen, M., Sundram, U., Bashey, S., Sutherland, K., Salva, K., Wood, G. S., … Kim, Y. H. (2012). Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression. BLOOD, 120(21).

Bexarotene is highly active in the treatment of subcutaneous Panniculitis-like T-cell lymphoma.
Molina, A. M., Advani, R., Reddy, S., Hoppe, R., Friedberg, J. W., Sadan, S., … Horwitz, S. M. (2005). Bexarotene is highly active in the treatment of subcutaneous Panniculitis-like T-cell lymphoma. BLOOD, 106(11), 934A–934A.

Primary cutaneous CD30+ anaplastic large cell lymphoma: Analysis of the Stanford series reveals two clinical subsets of patients.
Reddy, S. A., Liu, H., Kohler, S., Hoppe, R. T., & Kim, Y. H. (2004). Primary cutaneous CD30+ anaplastic large cell lymphoma: Analysis of the Stanford series reveals two clinical subsets of patients. BLOOD, 104(11), 226B–226B.

Out on a limb: prognostic factors in primary cutaneous anaplastic large cell lymphoma
Jones, C. R., Kohler, S., Cobb, K., Friedman, G. D., Reddy, S., Adrani, R., … Kim, Y. (2007). Out on a limb: prognostic factors in primary cutaneous anaplastic large cell lymphoma. Presented at the 68th Annual Meeting of the Society-for-Investigative-Dermatology, LOS ANGELES,CA,CA,CA: NATURE PUBLISHING GROUP.

Prognostic factors in primary cutaneous anaplastic large cell lymphoma: Clinical and molecular characterization of a subset with worse outcome
Woo, D., Jones, C., Vanoli-Storz, M., Kohler, S., Reddy, S., Advani, R., … Kim, Y. (2007). Prognostic factors in primary cutaneous anaplastic large cell lymphoma: Clinical and molecular characterization of a subset with worse outcome. BLOOD, 110(11), 1045A–1045A.

Pooled analyses of two international, multicenter clinical studies of romidepsin in 167 patients with cutaneous T-cell lymphoma (CTCL)
Demierre, M., Whittaker, S., Kim, Y., Kim, E., Piekarz, R., Prince, M., … BATES, S. (2009). Pooled analyses of two international, multicenter clinical studies of romidepsin in 167 patients with cutaneous T-cell lymphoma (CTCL). JOURNAL OF CLINICAL ONCOLOGY, 27(15).

Characterization of Cyclic Hematologic Changes Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor
Whittaker, S., Kim, E. J., Prince, M., Demierre, M. F., Giver, C., Lonial, S., … Bates, S. (2009). Characterization of Cyclic Hematologic Changes Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor. BLOOD, 114(22), 1425–1425.

Radiation therapy is an effective treatment for refractory Woringer-Kolopp disease
Lee, I. L., Viakhireva, N., Cesca, C., Lee, P., Kohler, S., Hoppe, R., & Kim, Y. (2008). Radiation therapy is an effective treatment for refractory Woringer-Kolopp disease. Presented at the International Investigative Dermatology Meeting, KYOTO,JAPAN,JAPAN,JAPAN,JAPAN,JAPAN: NATURE PUBLISHING GROUP.

Exploratory study of brentuximab vedotin (SGN-35), a novel monoclonal antibody-drug-conjugate against CD30, in mycosis fungoides (MF) and Sezary syndrome (SS) demonstrates clinical responses regardless of CD30 expression levels
Bashey, S., Krathen, M., Sutherland, K., Sundram, U., Lingala, B., Horwitz, S., … Kim, Y. (2012). Exploratory study of brentuximab vedotin (SGN-35), a novel monoclonal antibody-drug-conjugate against CD30, in mycosis fungoides (MF) and Sezary syndrome (SS) demonstrates clinical responses regardless of CD30 expression levels. Presented at the 75th Annual Meeting of the Society-for-Investigative-Dermatology, RALEIGH,NC,NC,NC,NC,NC,NC,NC,NC: NATURE PUBLISHING GROUP.

A prospective trial of low-dose total skin electron beam therapy in mycosis fungoides and proposal of a new clinically meaningful endpoint
Bashey, S., Harrison, C., Navi, D., Lingala, B., Armstrong, R., Weng, W.-K., … Hoppe, R. (2011). A prospective trial of low-dose total skin electron beam therapy in mycosis fungoides and proposal of a new clinically meaningful endpoint. WILEY-BLACKWELL.

EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma
Kempf, W., Pfaltz, K., Vermeer, M. H., Cozzio, A., Ortiz-Romero, P. L., Bagot, M., … Willemze, R. (2011). EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. BLOOD, 118(15), 4024–4035.

Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)
Olsen, E., Vonderheid, E., Pimpinelli, N., Willemze, R., Kim, Y., Knobler, R., … Whittaker, S. (2007). Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). BLOOD, 110(6), 1713–1722.

European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas
Senff, N. J., Noordijk, E. M., Kim, Y. H., Bagot, M., Berti, E., Cerroni, L., … Willemze, R. (2008). European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. BLOOD, 112(5), 1600–1609.

Sezary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)
Olsen, E. A., Rook, A. H., Zic, J., Kim, Y., Porcu, P., Querfeld, C., … Duvic, M. (2011). Sezary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 64(2), 352–404.

TLR9 agonist immunomodulator treatment of cutaneous T-cell lymphoma (CTCL) with CPG7909.
Kim, Y., Girardi, M., Duvic, M., Kuzel, T., Rook, A., Link, B., … Schmalbach, T. (2004). TLR9 agonist immunomodulator treatment of cutaneous T-cell lymphoma (CTCL) with CPG7909. BLOOD, 104(11), 212A–213A.

The largest single-center US study of cutaneous CD30+lymphoproliferative disorders
Liu, H., Kohler, S., Harvell, J., Hoppe, R., & Kim, Y. (2002). The largest single-center US study of cutaneous CD30+lymphoproliferative disorders. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 119(1), 237–37.

Clinical and pathological spectrum of post-transplant lymphoproliferative disorders with skin involvement
Wee, S., Horowitz, S., Kohler, S., & Kim, Y. H. (2002). Clinical and pathological spectrum of post-transplant lymphoproliferative disorders with skin involvement. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 119(1), 243–243.

Management with topical nitrogen mustard in mycosis fungoides: Update of the Stanford experience
Kim, Y. H., & Hoppe, R. T. (2002). Management with topical nitrogen mustard in mycosis fungoides: Update of the Stanford experience. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 119(1), 234–34.

Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides
de Coninck, E., Kim, Y., Varghese, A., & Hoppe, R. (2001). Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 117(2), 534–534.

Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-Cell lymphoma: Results of a phase II study
Advani, R., Hymes, K., Pohlman, B., Jacobsen, E., McDonnell, J., Belt, R., … Foss, F. (2007). Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-Cell lymphoma: Results of a phase II study. BLOOD, 110(11), 1012A–1012A.

HuMax-CD4, fully human monoclonal antibody: Phase II trial in cutaneous T cell lymphoma
Kim, Y. H., Obitz, E., Iversen, L., Oesterborg, A., Whittaker, S., Illidge, T. M., … Knox, S. J. (2004). HuMax-CD4, fully human monoclonal antibody: Phase II trial in cutaneous T cell lymphoma. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 122(3), A57–A57.

Changes in quality of life (QOL) for patients (pts) enrolled in a phase III trial of treatment with a diphtheria toxin fusion protein (DAB(389)IL-2) for mycosis fungoides (MF).
Liepa, A., Bennett, C. L., Yarnold, P. R., Enas, N., Lozano, J., Kuzel, T., … Nichols, J. (1997). Changes in quality of life (QOL) for patients (pts) enrolled in a phase III trial of treatment with a diphtheria toxin fusion protein (DAB(389)IL-2) for mycosis fungoides (MF). BLOOD, 90(10), 3924–3924.

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma
Olsen, E., Duvic, M., Frankel, A., Kim, Y., Martin, A., Vonderheid, E., … Nichols, J. (2001). Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 19(2), 376–388.

Non-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines
Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., … Naganuma, M. (2013). Non-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(3), 257–73.

Non-Hodgkin's Lymphomas
Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Bellam, N., … Zafar, N. (2011). Non-Hodgkin's Lymphomas. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(5), 484–560.

Topical Chemotherapy in Cutaneous T-cell Lymphoma Positive Results of a Randomized, Controlled, Multicenter Trial Testing the Efficacy and Safety of a Novel Mechlorethamine, 0.02%, Gel in Mycosis Fungoides
Lessin, S. R., Duvic, M., Guitart, J., Pandya, A. G., Strober, B. E., Olsen, E. A., … Kim, Y. H. (2013). Topical Chemotherapy in Cutaneous T-cell Lymphoma Positive Results of a Randomized, Controlled, Multicenter Trial Testing the Efficacy and Safety of a Novel Mechlorethamine, 0.02%, Gel in Mycosis Fungoides. JAMA DERMATOLOGY, 149(1), 25–32.

Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach.
Horwitz, S. M., Olsen, E. A., Duvic, M., Porcu, P., & Kim, Y. H. (2008). Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach. Journal of the National Comprehensive Cancer Network , 6(4), 436–442.

Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines
Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., … Dwyer, M. A. (2012). Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(12), 1487–98.

Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma.
Weng, W.-K., Armstrong, R., Arai, S., Desmarais, C., Hoppe, R., & Kim, Y. H. (2013). Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma. Science Translational Medicine, 5(214), 214ra171-?

Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome.
Querfeld, C., Rosen, S. T., Guitart, J., Duvic, M., Kim, Y. H., Dusza, S. W., & Kuzel, T. M. (2014). Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome. Blood, 123(8), 1159–1166.

Multicenter Case Series of Indolent Small/Medium-Sized CD8+ Lymphoid Proliferations With Predilection for the Ear and Face.
Li, J. Y., Guitart, J., Pulitzer, M. P., Subtil, A., Sundram, U., Kim, Y., … Querfeld, C. (2014). Multicenter Case Series of Indolent Small/Medium-Sized CD8+ Lymphoid Proliferations With Predilection for the Ear and Face. American Journal of Dermatopathology, 36(5), 402–8.

Non-Hodgkin's lymphomas, version 2.2014.
Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2014). Non-Hodgkin's lymphomas, version 2.2014. Journal of the National Comprehensive Cancer Network , 12(6), 916–46.

Bexarotene Is Active Against Subcutaneous Panniculitis-Like T-Cell Lymphoma in Adult and Pediatric Populations
Mehta, N., Wayne, A. S., Kim, Y. H., Hale, G. A., Alvarado, C. S., Myskowski, P., … Horwitz, S. (2012). Bexarotene Is Active Against Subcutaneous Panniculitis-Like T-Cell Lymphoma in Adult and Pediatric Populations. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 12(1), 20–25.

Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK (R))
Duvic, M., Kuzel, T., Olsen, E. A., Martin, A. G., Foss, F. M., Kim, Y. H., … Liepa, A. (2002). Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK (R)). CLINICAL LYMPHOMA, 2(4), 222–228.

Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30(+) primary cutaneous lymphoproliferative disorders and Hodgkin's disease
Wood, G. S., Hardman, D. L., Boni, R., Dummer, R., Kim, Y. H., SMOLLER, B. R., … Burg, G. (1996). Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30(+) primary cutaneous lymphoproliferative disorders and Hodgkin's disease. BLOOD, 88(5), 1765–70.

Intralymphatic Cutaneous Anaplastic Large Cell Lymphoma/Lymphomatoid Papulosis: Expanding the Spectrum of CD30-positive Lymphoproliferative Disorders.
Samols, M. A., Su, A., Ra, S., Cappel, M. A., Louissant, A., Knudson, R. A., … Gratzinger, D. (2014). Intralymphatic Cutaneous Anaplastic Large Cell Lymphoma/Lymphomatoid Papulosis: Expanding the Spectrum of CD30-positive Lymphoproliferative Disorders. American Journal of Surgical Pathology, 38(9), 1203–11.

Evidence against a role for human T-cell lymphotrophic virus type I (HTLV-I) in the pathogenesis of American cutaneous T-cell lymphoma
Wood, G. S., Salvekar, A., Schaffer, J., CROOKS, C. F., HENGHOLD, W., Fivenson, D. P., … SMOLLER, B. R. (1996). Evidence against a role for human T-cell lymphotrophic virus type I (HTLV-I) in the pathogenesis of American cutaneous T-cell lymphoma. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 107(3), 301–307.

Minimal Residual Disease Monitoring with High-Throughput Sequencing of T Cell Receptors in Cutaneous T Cell Lymphoma
Weng, W.-K., Armstrong, R., Arai, S., Desmarais, C., Hoppe, R., & Kim, Y. H. (2013). Minimal Residual Disease Monitoring with High-Throughput Sequencing of T Cell Receptors in Cutaneous T Cell Lymphoma. SCIENCE TRANSLATIONAL MEDICINE, 5(214).

Outcomes after diagnosis of mycosis fungoides and Sézary syndrome before 30 years of age: a population-based study.
Ai, W. Z., Keegan, T. H., Press, D. J., Yang, J., Pincus, L. B., Kim, Y. H., & Chang, E. T. (2014). Outcomes after diagnosis of mycosis fungoides and Sézary syndrome before 30 years of age: a population-based study. JAMA Dermatology, 150(7), 709–15.

Non-Hodgkin's Lymphomas, Version 4.2014.
Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2014). Non-Hodgkin's Lymphomas, Version 4.2014. Journal of the National Comprehensive Cancer Network , 12(9), 1282–1303.

Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).
Dummer, R., Duvic, M., Scarisbrick, J., Olsen, E. A., Rozati, S., Eggmann, N., … Kim, Y. H. (2014). Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome). Annals of Oncology , 25(9), 1807–1812.

Prognostic factors, prognostic indices and staging in mycosis fungoides and Sezary syndrome: where are we now?
Scarisbrick, J. J., Kim, Y. H., Whittaker, S. J., Wood, G. S., Vermeer, M. H., Prince, H. M., & Quaglino, P. (2014). Prognostic factors, prognostic indices and staging in mycosis fungoides and Sezary syndrome: where are we now? BRITISH JOURNAL OF DERMATOLOGY, 170(6), 1226–1236.

Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials.
Hoppe, R. T., Harrison, C., Tavallaee, M., Bashey, S., Sundram, U., Li, S., … Kim, Y. H. (2015). Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials. Journal of the American Academy of Dermatology, 72(2), 286–92.

Utility of high-throughput sequencing of T cell receptor gene rearrangement to improve diagnosis in cutaneous T cell lymphoma
Rozati, S., Weng, W., Tavallaee, M., Kim, J., Rieger, K., Armstrong, R., … Kim, Y. H. (2014). Utility of high-throughput sequencing of T cell receptor gene rearrangement to improve diagnosis in cutaneous T cell lymphoma. Presented at the Annual Meeting of the Society-for-Investigative-Dermatology (SID), ALBUQUERQUE,NM,NM,NM,NM,NM,NM: NATURE PUBLISHING GROUP.

Low Dose (12 Gy) Total Skin Electron Beam Therapy (TSEBT) for Mycosis Fungoides (mf): Results of Three Phase 2 Clinical Trials
Hoppe, R. T., Harrison, C., Tavallaee, M., Bashey, S., Li, S., Million, L., … Kim, Y. H. (2014). Low Dose (12 Gy) Total Skin Electron Beam Therapy (TSEBT) for Mycosis Fungoides (mf): Results of Three Phase 2 Clinical Trials. Presented at the 56th Annual Meeting of the American-Society-for-Radiation-Oncology, SAN FRANCISCO,CA,CA,CA,CA: ELSEVIER SCIENCE INC.

A multicenter, open-label, randomized, phase I/II study evaluating the safety and efficacy of low-dose (12 Gy) total skin electron beam therapy (TSEBT) combined with vorinostat versus low-dose TSEBT monotherapy in patients with mycosis fungoides
Bashey, S., Tavallaee, M., Duvic, M., Dabaja, B., Talpur, R., Wilson, L., … Kim, Y. H. (2014). A multicenter, open-label, randomized, phase I/II study evaluating the safety and efficacy of low-dose (12 Gy) total skin electron beam therapy (TSEBT) combined with vorinostat versus low-dose TSEBT monotherapy in patients with mycosis fungoides. Presented at the Annual Meeting of the Society-for-Investigative-Dermatology (SID), ALBUQUERQUE,NM,NM,NM,NM: NATURE PUBLISHING GROUP.

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.
Duvic, M., Pinter-Brown, L. C., Foss, F. M., Sokol, L., Jorgensen, J. L., Challagundla, P., … Kim, Y. H. (2015). Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood, 125(12), 1883–89.

Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2.
Ungewickell, A., Bhaduri, A., Rios, E., Reuter, J., Lee, C. S., Mah, A., … Khavari, P. A. (2015). Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2. Nature Genetics, 47(9), 1056–60.

Multidisciplinary Care in the Management of Patients With Cutaneous Lymphoma: A Perspective
Kim, Y. H. (2010). Multidisciplinary Care in the Management of Patients With Cutaneous Lymphoma: A Perspective. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 10, S106–S108.

Primary Cutaneous Gamma-Delta T-Cell Lymphoproliferative Disorder in a 3-Year-Old Boy.
Soon, C. W. M., Link, M., Kim, Y. H., & Kim, J. (2015). Primary Cutaneous Gamma-Delta T-Cell Lymphoproliferative Disorder in a 3-Year-Old Boy. American Journal of Dermatopathology, 37(7), 567–69.

Lymph node involvement by mycosis fungoides and Sezary syndrome mimicking angioimmunoblastic T-cell Lymphoma
LeBlanc, R. E., Lefterova, M. I., Suarez, C. J., Tavallaee, M., Kim, Y. H., Schrijver, I., … Gratzinger, D. (2015). Lymph node involvement by mycosis fungoides and Sezary syndrome mimicking angioimmunoblastic T-cell Lymphoma. HUMAN PATHOLOGY, 46(9), 1382–89.

Occult Dermal Lymphatic Involvement Is Frequent in Primary Cutaneous Anaplastic Large Cell Lymphoma.
Gratzinger, D., Million, L., & Kim, Y. H. (2015). Occult Dermal Lymphatic Involvement Is Frequent in Primary Cutaneous Anaplastic Large Cell Lymphoma. American Journal of Dermatopathology, 37(10), 767–70.

Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2
Ungewickell, A., Bhaduri, A., Rios, E., Reuter, J., Lee, C. S., Mah, A., … Khavari, P. A. (2015). Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2. NATURE GENETICS, 47(9), 1056-?

Outcomes After Diagnosis of Mycosis Fungoides and Sezary Syndrome Before 30 Years of Age A Population-Based Study
Ai, W. Z., Keegan, T. H., Press, D. J., Yang, J., Pincus, L. B., Kim, Y. H., & Chang, E. T. (2014). Outcomes After Diagnosis of Mycosis Fungoides and Sezary Syndrome Before 30 Years of Age A Population-Based Study. JAMA DERMATOLOGY, 150(7), 709–15.

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., … Horwitz, S. M. (2015). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of Clinical Oncology , 33(32), 3750–58.

Subcutaneous Panniculitis-Like T-Cell Lymphoma: Pediatric Case Series Demonstrating Heterogeneous Presentation and Option for Watchful Waiting
Johnston, E. E., LeBlanc, R. E., Kim, J., Chung, J., Balagtas, J., Kim, Y. H., & Link, M. P. (2015). Subcutaneous Panniculitis-Like T-Cell Lymphoma: Pediatric Case Series Demonstrating Heterogeneous Presentation and Option for Watchful Waiting. PEDIATRIC BLOOD & CANCER, 62(11), 2025–28.

Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma
Kim, E. J., Kim, Y. H., Rook, A. H., Lerner, A., Duvic, M., Reddy, S., … Whittaker, S. (2015). Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. LEUKEMIA & LYMPHOMA, 56(10), 2847–54.

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., … Horwitz, S. M. (2015). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of Clinical Oncology , 33(32), 3750–58.

Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.
Scarisbrick, J. J., Prince, H. M., Vermeer, M. H., Quaglino, P., Horwitz, S., Porcu, P., … Kim, Y. H. (2015). Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. Journal of Clinical Oncology , 33(32), 3766–73.

Diffuse Large B-Cell Lymphoma Version 1.2016 Clinical Practice Guidelines in Oncology
Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2016). Diffuse Large B-Cell Lymphoma Version 1.2016 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(2), 196–231.

Experimental treatment strategies in primary cutaneous T-cell lymphomas
Rozati, S., & Kim, Y. H. (2016). Experimental treatment strategies in primary cutaneous T-cell lymphomas. CURRENT OPINION IN ONCOLOGY, 28(2), 166–71.

Useful Parameters for Distinguishing Subcutaneous Panniculitis-like T-Cell Lymphoma From Lupus Erythematosus Panniculitis
LeBlanc, R. E., Tavallaee, M., Kim, Y. H., & Kim, J. (2016). Useful Parameters for Distinguishing Subcutaneous Panniculitis-like T-Cell Lymphoma From Lupus Erythematosus Panniculitis. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 40(6), 745–54.

Neurotropic Gamma-Delta T-Cell Lymphoma With CD30-Positive Lymphoid Infiltrates
Gammon, B., Gammon, B. R., Kim, Y. H., & Kim, J. (2016). Neurotropic Gamma-Delta T-Cell Lymphoma With CD30-Positive Lymphoid Infiltrates. AMERICAN JOURNAL OF DERMATOPATHOLOGY, 38(9), E133–E136.

Individuality and variation of personal regulomes in primary human T cells.
Qu, K., Zaba, L. C., Giresi, P. G., Li, R., Longmire, M., Kim, Y. H., … Chang, H. Y. (2015). Individuality and variation of personal regulomes in primary human T cells. Cell Systems, 1(1), 51–61.

Non-Hodgkin's Lymphomas, Version 3.2016 Featured Updates to the NCCN Guidelines
Horwitz, S. M., Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., … Porcu, P. (2016). Non-Hodgkin's Lymphomas, Version 3.2016 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(9), 1067–79.

Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome.
Corbin, Z. A., Nguyen-Lin, A., Li, S., Rahbar, Z., Tavallaee, M., Vogel, H., … Nagpal, S. (2017). Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome. Journal of Neuro-Oncology.

Individuality and Variation of Personal Regulomes in Primary Human T Cells
Qu, K., Zaba, L. C., Giresi, P. G., Li, R., Longmire, M., Kim, Y. H., … Chang, H. Y. (2015). Individuality and Variation of Personal Regulomes in Primary Human T Cells. CELL SYSTEMS, 1(1), 51–61.

Zosteriform Mycosis Fungoides: A New Clinical Presentation With a Dermatomal Distribution.
Rieger, K. E., Kim, J., & Kim, Y. H. (2017). Zosteriform Mycosis Fungoides: A New Clinical Presentation With a Dermatomal Distribution. The American Journal of Dermatopathology, 39(2), e17–e18.

NCCN Guidelines (R) Insights Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017 Featured Updates to the NCCN Guidelines
Wierda, W. G., Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2017). NCCN Guidelines (R) Insights Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(3), 293–311.

Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors.
Qu, K., Zaba, L. C., Satpathy, A. T., Giresi, P. G., Li, R., Jin, Y., … Chang, H. Y. (2017). Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors. Cancer Cell.

Localized skin-limited blastic plasmacytoid dendritic cell neoplasm: A subset with possible durable remission without transplantation.
Amitay-Laish, I., Sundram, U., Hoppe, R. T., Hodak, E., Medeiros, B. C., & Kim, Y. H. (2017). Localized skin-limited blastic plasmacytoid dendritic cell neoplasm: A subset with possible durable remission without transplantation. JAAD Case Reports, 3(4), 310–15.

JUNCTIONAL EPIDERMOLYSIS-BULLOSA SKIN GRAFTED TO THE SCID MOUSE SHOWS PRESERVATION OF THE DISEASE PHENOTYPE
MARINKOVICH, M. P., WOODLEY, D. T., WATANABE, G. L., JENSEN, R. A., CANTRELL, C. F., BANER, E. A., … KIM, Y. H. (1995). JUNCTIONAL EPIDERMOLYSIS-BULLOSA SKIN GRAFTED TO THE SCID MOUSE SHOWS PRESERVATION OF THE DISEASE PHENOTYPE. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 104(4), 603.

Vorinostat (Suberoylanilide hydroxamic acid, SAHA) provides prolonged clinical benefit to advanced cutaneous T-Cell lymphoma patients: Updated results of the phase IIb multicenter clinical trial.
Duvic, M., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., … Olsen, E. A. (2006). Vorinostat (Suberoylanilide hydroxamic acid, SAHA) provides prolonged clinical benefit to advanced cutaneous T-Cell lymphoma patients: Updated results of the phase IIb multicenter clinical trial. BLOOD. AMER SOC HEMATOLOGY.

The Systemic Effects of Vorinostat in Patients (Pts) with Cutaneous T-Cell Lymphoma (CTCL): Post-Hoc Analyses in Pts with High Blood Tumor Burden.
Duvic, M., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., … Olsen, E. A. (2009). The Systemic Effects of Vorinostat in Patients (Pts) with Cutaneous T-Cell Lymphoma (CTCL): Post-Hoc Analyses in Pts with High Blood Tumor Burden. BLOOD. AMER SOC HEMATOLOGY.

Transcript-indexed ATAC-seq for precision immune profiling.
Satpathy, A. T., Saligrama, N., Buenrostro, J. D., Wei, Y., Wu, B., Rubin, A. J., … Chang, H. Y. (2018). Transcript-indexed ATAC-seq for precision immune profiling. Nature Medicine.

Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome.
Dai, J., Almazan, T. H., Hong, E. K., Khodadoust, M. S., Arai, S., Weng, W.-K. K., & Kim, Y. H. (2018). Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome. JAMA Dermatology.

NCCN Guidelines (R) Insights T-Cell Lymphomas, Version 2.2018 Featured Updates to the NCCN Guidelines
Horwitz, S. M., Ansell, S. M., Ai, W. Z., Barnes, J., Barta, S. K., Choi, M., … Sundar, H. (2018). NCCN Guidelines (R) Insights T-Cell Lymphomas, Version 2.2018 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 16(2), 123–35.

Variability in the Expression of Immunohistochemical Markers: Implications for Biomarker Interpretation in Cutaneous T-Cell Lymphoma
Rahbar, Z., Li, S., Tavallaee, M., Novoa, R. A., Kim, J., & Kim, Y. H. (2018). Variability in the Expression of Immunohistochemical Markers: Implications for Biomarker Interpretation in Cutaneous T-Cell Lymphoma. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 138(5), 1204–6.

The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sezary Syndrome A Multi-institutional and International Pathology Study
Gru, A. A., Kim, J., Pulitzer, M., Guitart, J., Battistella, M., Wood, G. S., … Kim, Y. H. (2018). The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sezary Syndrome A Multi-institutional and International Pathology Study. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 42(6), 726–34.

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
Prince, H. M., Kim, Y. H., Horwitz, S. M., Dummer, R., Scarisbrick, J., Quaglino, P., … Duvic, M. (2017). Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. LANCET, 390(10094), 555–66.

Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sezary Syndrome (SS)
Weng, W.-K., Armstrong, R., Arai, S., Johnston, L., Laport, G. G., Lowsky, R., … Kim, Y. H. (2014). Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sezary Syndrome (SS). BLOOD, 124(21).

Use of High-Throughput Sequencing (HTS) of TCR beta to Determine the Kinetics of Graft-Versus-Lymphoma (GVL) Effect and T-Cell Repertoire Profiles after Allogeneic Transplant
Weng, W.-K., Armstrong, R., Arai, S., Hoppe, R. T., Meyer, E. H., & Kim, Y. H. (2014). Use of High-Throughput Sequencing (HTS) of TCR beta to Determine the Kinetics of Graft-Versus-Lymphoma (GVL) Effect and T-Cell Repertoire Profiles after Allogeneic Transplant. BLOOD. AMER SOC HEMATOLOGY.

A Cutaneous Lymphoma International Consortium 'CLIC' study of Prognostic Parameters in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Progress Towards Establishing a Prognostic Index to Augment Clinical Staging
Scarisbrick, J. J., Quaglino, P., Vermeer, M., Whittaker, S., Wood, G. S., Duvic, M., … Kim, Y. H. (2014). A Cutaneous Lymphoma International Consortium 'CLIC' study of Prognostic Parameters in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Progress Towards Establishing a Prognostic Index to Augment Clinical Staging. BLOOD. AMER SOC HEMATOLOGY.

Graft-Versus-Lymphoma Effect After Non-Myeloablative Allogeneic Transplant Induces Molecular Remission Assessed by High-Throughput Sequencing of T Cell Receptor in Patients with Advanced Stage Mycosis Fungoides and Sezary Syndrome
Weng, W.-K., Armstrong, R., Arai, S., Sutherland, K., Hoppe, R. T., & Kim, Y. H. (2011). Graft-Versus-Lymphoma Effect After Non-Myeloablative Allogeneic Transplant Induces Molecular Remission Assessed by High-Throughput Sequencing of T Cell Receptor in Patients with Advanced Stage Mycosis Fungoides and Sezary Syndrome. BLOOD. AMER SOC HEMATOLOGY.

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides or Sezary Syndrome: Final Results Show Significant Clinical Activity and Suggest Correlation with CD30 Expression
Kim, Y. H., Tavallaee, M., Rozati, S., Sundram, U., Salva, K., Wood, G. S., … Horwitz, S. M. (2014). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides or Sezary Syndrome: Final Results Show Significant Clinical Activity and Suggest Correlation with CD30 Expression. BLOOD, 124(21).

Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma
Kohrt, H. E., Chu, J., Brody, J., Czerwinski, D. K., Chester, C., Sadaram, M., … Levy, R. (2014). Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma. BLOOD, 124(21).

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim, Y. H., Bagot, M., Pinter-Brown, L., Rook, A. H., Porcu, P., Horwitz, S. M., … Duvic, M. (2018). Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. The Lancet. Oncology.

Pembrolizumab in mycosis fungoides and Sezary syndrome: Updated results of the CITN multicenter Phase 2 study
Khodadoust, M. S., Rook, A. H., Porcu, P., Foss, F., Moskowitz, A., Shustov, A. R., … Kim, Y. H. (2018). Pembrolizumab in mycosis fungoides and Sezary syndrome: Updated results of the CITN multicenter Phase 2 study. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.

Epigenetically Enhanced PDT Induces Significantly Higher Levels of Multiple Extrinsic Pathway Apoptotic Factors than Standard PDT, Resulting in Greater Extrinsic and Overall Apoptosis of Cutaneous T-cell Lymphoma
Salva, K. A., Kim, Y. H., Rahbar, Z., & Wood, G. S. (2018). Epigenetically Enhanced PDT Induces Significantly Higher Levels of Multiple Extrinsic Pathway Apoptotic Factors than Standard PDT, Resulting in Greater Extrinsic and Overall Apoptosis of Cutaneous T-cell Lymphoma. PHOTOCHEMISTRY AND PHOTOBIOLOGY, 94(5), 1058–65.

Utility of CD30, Ki-67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation.
Raghavan, S. S., Hong, E. K., Kim, Y. H., & Kim, J. (2018). Utility of CD30, Ki-67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation. Journal of Cutaneous Pathology.

Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin.
Cabell, C., Bates, S., Piekarz, R., Whittaker, S., Kim, Y. H., Currie, M., … Burris, H. A. (2009). Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin. BLOOD, 114(22), 1428–29.

Phase 1 Trial of Cobomarsen, an Inhibitor of Mir-155, in Cutaneous T Cell Lymphoma
Querfeld, C., Foss, F. M., Kim, Y. H., Pinter-Brown, L., William, B. M., Porcu, P., … Marshall, W. S. (2018). Phase 1 Trial of Cobomarsen, an Inhibitor of Mir-155, in Cutaneous T Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.

Durable Responses with Pembrolizumab in Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Final Results from a Phase 2 Multicenter Study
Khodadoust, M. S., Rook, A., Porcu, P., Foss, F. M., Moskowitz, A. J., Shustov, A. R., … Kim, Y. H. (2018). Durable Responses with Pembrolizumab in Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Final Results from a Phase 2 Multicenter Study. BLOOD. AMER SOC HEMATOLOGY.

The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Horwitz, S. M., Feldman, T. A., Hess, B. T., Khodadoust, M. S., Kim, Y. H., Munoz, J., … Hamlin, P. A. (2018). The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.

The Combination of Duvelisib, a PI3K-delta,gamma Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts
Horwitz, S. M., Moskowitz, A. J., Jacobsen, E. D., Mehta-Shah, N., Khodadoust, M. S., Fisher, D. C., … Weinstock, D. M. (2018). The Combination of Duvelisib, a PI3K-delta,gamma Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts. BLOOD. AMER SOC HEMATOLOGY.

Volumetric modulated arc therapy and 3-dimensional printed bolus in the treatment of refractory primary cutaneous gamma delta lymphoma of the bilateral legs.
Obeid, J.-P., Gutkin, P. M., Lewis, J., Skinner, L., Wang, E. B., Khodadoust, M. S., … Hiniker, S. M. (2019). Volumetric modulated arc therapy and 3-dimensional printed bolus in the treatment of refractory primary cutaneous gamma delta lymphoma of the bilateral legs. Practical Radiation Oncology.

Marked improvement in staging accuracy in mycosis fungoides/Sezary syndrome using integrated positron emission tomography and computed tomography (PET/CT)
Tsai, E. Y., Taur, A., Espinosa, L., Quon, A., Dick, S. E., Chow, S., … Kim, Y. H. (2004). Marked improvement in staging accuracy in mycosis fungoides/Sezary syndrome using integrated positron emission tomography and computed tomography (PET/CT). BLOOD, 104(11), 854A–855A.

A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT)
Kim, Y. H., Hoppe, R. T., Rook, A. H., Maity, A., Geskin, L. J., Horowitz, D. P., … Basile, L. A. (2016). A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT). BLOOD. AMER SOC HEMATOLOGY.

The clinical spectrum of cutaneous B-cell lymphomas (CBCL): Excellent prognosis for patients with disease limited to the skin.
Mraz-Gernhard, S. M., Horwitz, S., Kim, Y. H., Kohler, S., & Hoppe, R. (2000). The clinical spectrum of cutaneous B-cell lymphomas (CBCL): Excellent prognosis for patients with disease limited to the skin. BLOOD, 96(11), 329A.

Natural killer/natural killer-like T-cell lymphoma (CD56+) presenting in the skin: A study of clinical and pathologic characteristics affecting survival.
Mraz-Gernhard, S. M., Hoppe, R. T., Natkunam, Y., Leboit, P., Kohler, S., & Kim, Y. H. (2000). Natural killer/natural killer-like T-cell lymphoma (CD56+) presenting in the skin: A study of clinical and pathologic characteristics affecting survival. BLOOD, 96(11), 124A–125A.

Combined BIOMED-2 clonality assays for IGH and IGK and assessment of t(14;18) on formalin-fixed, paraffin embedded tissues effectively separates primary cutaneous B cell lymphomas from reactive cutaneous lymphoid hyperplasia.
Morales, A. V., Seo, K., Arber, D. A., Kohler, S., Kim, Y. H., & Sundram, U. (2007). Combined BIOMED-2 clonality assays for IGH and IGK and assessment of t(14;18) on formalin-fixed, paraffin embedded tissues effectively separates primary cutaneous B cell lymphomas from reactive cutaneous lymphoid hyperplasia. BLOOD, 110(11), 772A–773A.

Response to oral forodesine in refractory cutaneous T-Cell lymphoma: Interim results of a phase I/II study
Duvic, M., Forero-Torres, A., Foss, F., Olsen, E., & Kim, Y. (2007). Response to oral forodesine in refractory cutaneous T-Cell lymphoma: Interim results of a phase I/II study. BLOOD, 110(11), 44A.

Zanolimumab, a fully human monoclonal antibody: early results of an ongoing clinical trial in patients with CD4(+) mycosis fungoides (MF) type CTCL(stage IB-IVB) who are refractory or intolerant to targretin and one other standard therapy.
Duvic, M., Kim, Y., Korman, N. J., Boh, E., Lerner, A., Heffernan, M. P., … Baadsgaard, O. (2006). Zanolimumab, a fully human monoclonal antibody: early results of an ongoing clinical trial in patients with CD4(+) mycosis fungoides (MF) type CTCL(stage IB-IVB) who are refractory or intolerant to targretin and one other standard therapy. BLOOD, 108(11), 772A.

Oral forodesine (Bcx-1777) is clinically active in refractory cutaneous T-cell lymphoma: Results of a phase I/II study.
Duvic, M., Forero-Torres, A., Foss, F., Olsen, E. A., & Kim, Y. (2006). Oral forodesine (Bcx-1777) is clinically active in refractory cutaneous T-cell lymphoma: Results of a phase I/II study. BLOOD, 108(11), 698A.

A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis
Knobler, R. M., French, L. E., Kim, Y., Bisaccia, E., Graninger, W., Nahavandi, H., … Braverman. (2006). A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 54(5), 793–99.

Novel treatment of cutaneous T cell lymphoma: Targeting TNFR2, an oncogene and marker of potent Tregs, with anti-TNFR2 antibodies
Torrey, H., Defusco, A., Baum, D., Rahbar, Z., Khodadoust, M., Kim, Y. H., & Faustman, D. (2017). Novel treatment of cutaneous T cell lymphoma: Targeting TNFR2, an oncogene and marker of potent Tregs, with anti-TNFR2 antibodies. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMC.

Long-Term Clinical Benefit to Anti-CCR4 Mogamulizumab: Results from the Phase 3 Mavoric Study in Previously Treated Cutaneous T-Cell Lymphoma (CTCL)
Bagot, M., Dalle, S., Sokol, L., Tsianakas, A., Musiek, A., Ortiz-Romero, P., … Kim, Y. H. (2018). Long-Term Clinical Benefit to Anti-CCR4 Mogamulizumab: Results from the Phase 3 Mavoric Study in Previously Treated Cutaneous T-Cell Lymphoma (CTCL). BLOOD, 132.

Measurement of Quality of Life in Patients with Mycosis Fungoides/Sezary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument
McCaffrey, S., Black, R. A., Nagao, M., Sepassi, M., Sharma, G., Thornton, S., … Braverman, J. (2019). Measurement of Quality of Life in Patients with Mycosis Fungoides/Sezary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument. JOURNAL OF MEDICAL INTERNET RESEARCH, 21(1), e11302.

Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma
Zhao, L., Okhovat, J.-P., Hong, E. K., Kim, Y. H., & Wood, G. S. (2019). Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma. NEOPLASIA, 21(1), 82–92.

Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy
Duvic, M., Bates, S. E., Piekarz, R., Eisch, R., Kim, Y. H., Lerner, A., … Whittaker, S. (2018). Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. LEUKEMIA & LYMPHOMA, 59(4), 880–87.

Phase 1 trial evaluating MRG-106, a synthetic inhibitor of microRNA-155, in patients with cutaneous t-cell lymphoma (CTCL).
Foss, F. M., Querfeld, C., Porcu, P., Kim, Y. H., Pacheco, T., Halwani, A. S., … Marshall, W. S. (2017). Phase 1 trial evaluating MRG-106, a synthetic inhibitor of microRNA-155, in patients with cutaneous t-cell lymphoma (CTCL). JOURNAL OF CLINICAL ONCOLOGY, 35.

Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma
Duvic, M., Kim, Y. H., Zinzani, P. L., & Horwitz, S. M. (2017). Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma. CLINICAL CANCER RESEARCH, 23(14), 3552–56.

An adolescent with granulomatous mycosis fungoides infiltrating skeletal muscle successfully treated with oral prednisone.
Lewis, D. J., Turkeltaub, A. E., Dai, J., Nagarajan, P., Rieger, K. E., Nunez, C. A., … Duvic, M. (2017). An adolescent with granulomatous mycosis fungoides infiltrating skeletal muscle successfully treated with oral prednisone. JAAD Case Reports, 3(4), 276–79.

Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas
Guitart, J., Martinez-Escala, M. E., Subtil, A., Duvic, M., Pulitzer, M. P., Olsen, E. A., … Kim, Y. H. (2017). Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas. MODERN PATHOLOGY, 30(5), 761–72.

First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results
Bagot, M., Porcu, P., Ram-Wolff, C., Khodadoust, M., Battistella, M., Marie-Cardine, A., … Kim, Y. (2016). First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results. BLOOD. AMER SOC HEMATOLOGY.

Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study
Kim, Y. H., Whittaker, S., Horwitz, S. M., Duvic, M., Dummer, R., Scarisbrick, J. J., … Prince, H. M. (2016). Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study. BLOOD, 128(22).

Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study
Khodadoust, M., Rook, A. H., Porcu, P., Foss, F. M., Moskowitz, A. J., Shustov, A. R., … Kim, Y. (2016). Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study. BLOOD. AMER SOC HEMATOLOGY.

KIR3DL2 is a novel target for antibody-therapy of T cell lymphomas
Chester, C., Lim, S., Marie-Cardine, A., Rajasekaran, N., Sicard, H., Kim, Y., & Kohrt, H. (2015). KIR3DL2 is a novel target for antibody-therapy of T cell lymphomas. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

Results from a Phase 1/2, Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma
Duvic, M., Horwitz, S. M., Kim, Y. H., Zinzani, P. L., Bhat, G., Sharma, P., & Yancik, S. (2015). Results from a Phase 1/2, Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma. BLOOD, 126(23).

HuMax-CD4, a fully human monoclonal antibody: Early results of an ngoing phase II trial in cutaneous T cell lymphoma
Obitz, E., Kim, Y. H., Iversen, L., Osterborg, A., Jensen, P., Baadsgaard, O., & Knox, S. J. (2003). HuMax-CD4, a fully human monoclonal antibody: Early results of an ngoing phase II trial in cutaneous T cell lymphoma. BLOOD, 102(11), 645A.

Efficacy and safety of mechlorethamine (MCH) 0.04% gel in mycosis fungoides (MF) after treatment with topical MCH 0.02%.
Kim, Y. H., Duvic, M., Guitart, J., & Lessin, S. (2014). Efficacy and safety of mechlorethamine (MCH) 0.04% gel in mycosis fungoides (MF) after treatment with topical MCH 0.02%. JOURNAL OF CLINICAL ONCOLOGY, 32(15).

Responses to romidepsin in patients with cutaneous T-cell lymphoma (CTCL) with tumors and/or folliculotropic involvement.
Foss, F. M., Duvic, M., Lerner, A., Rook, A., Whittaker, S., Kim, E. J., & Kim, Y. H. (2014). Responses to romidepsin in patients with cutaneous T-cell lymphoma (CTCL) with tumors and/or folliculotropic involvement. JOURNAL OF CLINICAL ONCOLOGY, 32(15).

Phase 3 study of anti-CCR4 monoclonal antibody mogamualizumab versus vorinostat in relapsed or refractory cutaneous T-cell lymphoma (CTCL)
Kim, Y. H., Bagot, M., Eradat, H. A., Carson, K. R., Greer, J. P., Kim, E. J., … Duvic, M. (2014). Phase 3 study of anti-CCR4 monoclonal antibody mogamualizumab versus vorinostat in relapsed or refractory cutaneous T-cell lymphoma (CTCL). JOURNAL OF CLINICAL ONCOLOGY, 32(15).

Responses to Romidepsin in Patients with Cutaneous T-Cell Lymphoma (CTCL) and Prior Treatment with Systemic Chemotherapy: Subanalysis from the Pivotal Phase 2 Study
Duvic, M., Kim, Y. H., Rook, A. H., Lerner, A., Robak, T., Samtsov, A., … Whittaker, S. (2014). Responses to Romidepsin in Patients with Cutaneous T-Cell Lymphoma (CTCL) and Prior Treatment with Systemic Chemotherapy: Subanalysis from the Pivotal Phase 2 Study. BLOOD, 124(21).

A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL)
Duvic, M., Kuzel, T. M., Dang, N. H., Prince, M., Feldman, T., Foss, F. M., … Kim, Y. H. (2014). A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL). BLOOD, 124(21).

Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sezary Syndrome
Ni, X., Jorgensen, J. L., Goswami, M., Challagundla, P., Decker, W. K., Kim, Y. H., & Duvic, M. A. (2015). Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sezary Syndrome. CLINICAL CANCER RESEARCH, 21(2), 274–85.

Correlation of Target Molecule Expression and Overall Response in Refractory Cutaneous T-Cell Lymphoma Patients Dosed with Mogamulizumab (KW-0761), a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4)
Duvic, M., Pinter-Brown, L., Foss, F., Sokol, L., Jorgensen, J., Ni, X., … Kim, Y. H. (2012). Correlation of Target Molecule Expression and Overall Response in Refractory Cutaneous T-Cell Lymphoma Patients Dosed with Mogamulizumab (KW-0761), a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4). BLOOD, 120(21).

Phase II Multicenter Trial of Lenalidomide: Clinical and Immunomodulatory Effects in Patients with CTCL
Querfeld, C., Rosen, S. T., Guitart, J., Duvic, M., Kim, Y. H., Goolsby, C., & Kuzel, T. (2011). Phase II Multicenter Trial of Lenalidomide: Clinical and Immunomodulatory Effects in Patients with CTCL. BLOOD, 118(21), 712.

Effects of Anti-CCR4 Antibody (KW-0761) on Regulatory T Cells and Natural Killer Cells in Patients with Cutaneous T-Cell Lymphoma
Ni, X., Jorgensen, J. L., Goswami, M., Challagundla, P., Decker, W. K., Kim, Y. H., & Duvic, M. (2011). Effects of Anti-CCR4 Antibody (KW-0761) on Regulatory T Cells and Natural Killer Cells in Patients with Cutaneous T-Cell Lymphoma. BLOOD, 118(21), 204–5.

Increased Risk of Second Malignancies In Young Patients with Mycosis Fungoides Diagnosed Before 30 Years of Age: A Population-Based Study
Ai, W., Keegan, T., Fish, K., Laura, P., Soon, C., Kim, Y. H., & Chang, E. (2010). Increased Risk of Second Malignancies In Young Patients with Mycosis Fungoides Diagnosed Before 30 Years of Age: A Population-Based Study. BLOOD, 116(21), 832.

Results of a Phase 1/2 Study for KW-0761, a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4), In CTCL Patients
Duvic, M., Pinter-Brown, L., Foss, F. M., Sokol, L., Jorgensen, J., Spitalny, G. L., & Kim, Y. H. (2010). Results of a Phase 1/2 Study for KW-0761, a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4), In CTCL Patients. BLOOD, 116(21), 424.

Pralatrexate Is Active in Cutaneous T-Cell Lymphoma (CTCL): Results of a Multicenter, Dose-Finding Trial
Horwitz, S. M., Duvic, M., Kim, Y., Zairi, J. M., Lechowicz, M. J., Myskowski, P., … O'Connor, O. A. (2009). Pralatrexate Is Active in Cutaneous T-Cell Lymphoma (CTCL): Results of a Multicenter, Dose-Finding Trial. BLOOD, 114(22), 379.

Bexarotene gel - A food and drug administration-approved skin-directed therapy for early-stage cutaneous T-cell lymphoma
Liu, H. L., & Kim, Y. H. (2002). Bexarotene gel - A food and drug administration-approved skin-directed therapy for early-stage cutaneous T-cell lymphoma. ARCHIVES OF DERMATOLOGY, 138(3), 398–99.

PHENOTYPIC REVERSION OF JUNCTIONAL EPIDERMOLYSIS-BULLOSA KERATINOCYTES BY THE INTRODUCTION OF A THERAPEUTIC LAMININ-5 CHAIN GENE
HOEFFLER, W. K., WANG, C. K., MATSUI, C., CANTRELL, C. F., GERECKE, D., KIM, Y., … BAUER, E. A. (1995). PHENOTYPIC REVERSION OF JUNCTIONAL EPIDERMOLYSIS-BULLOSA KERATINOCYTES BY THE INTRODUCTION OF A THERAPEUTIC LAMININ-5 CHAIN GENE. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 104(4), 597.

Recombinant Human Relaxin in the Treatment of Systemic Sclerosis With Diffuse Cutaneous Involvement A Randomized, Double-Blind, Placebo-Controlled Trial
Khanna, D., Clements, P. J., Furst, D. E., Korn, J. H., Ellman, M., Rothfield, N., … Seibold, J. R. (2009). Recombinant Human Relaxin in the Treatment of Systemic Sclerosis With Diffuse Cutaneous Involvement A Randomized, Double-Blind, Placebo-Controlled Trial. ARTHRITIS AND RHEUMATISM, 60(4), 1102–11.

Oral bexarotene is safe and effective in a phase II-III clinical trial in refractory or persistent early stage CTCL.
Duvic, M., Martin, A., Kim, Y., Olsen, E., Wood, G., & Yocum, R. (1999). Oral bexarotene is safe and effective in a phase II-III clinical trial in refractory or persistent early stage CTCL. BLOOD, 94(10), 659A.

DETERMINATION OF HUMAN PAPILLOMA-VIRUS IN NON-ANOGENITAL SQUAMOUS-CELL CARCINOMAS BY POLYMERASE CHAIN-REACTION
KIM, Y. H., SERKLAND, L. F., BAUER, E. A., & PALEFSKY, J. M. (1994). DETERMINATION OF HUMAN PAPILLOMA-VIRUS IN NON-ANOGENITAL SQUAMOUS-CELL CARCINOMAS BY POLYMERASE CHAIN-REACTION. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 102(4), 652.

RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA KERATINOCYTES SYNTHESIZE TYPE-VII COLLAGEN ALPHA-CHAINS OF NORMAL MOLECULAR-SIZE BUT THE ANCHORING FIBRIL ASSEMBLY IS IMPAIRED
IWASAKI, T., LAPIERE, J. C., UITTO, J., KIM, Y. H., & WOODLEY, D. T. (1993). RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA KERATINOCYTES SYNTHESIZE TYPE-VII COLLAGEN ALPHA-CHAINS OF NORMAL MOLECULAR-SIZE BUT THE ANCHORING FIBRIL ASSEMBLY IS IMPAIRED. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 193(2), 604–10.

RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA (RDEB) KERATINOCYTES SYNTHESIZE TYPE-VII (ANCHORING FIBRIL) COLLAGEN ALPHA-CHAINS OF NORMAL MOLECULAR-SIZE
IWASAKI, T., LAPIERE, J. C., UITTO, J., KIM, Y. H., & WOODLEY, D. T. (1993). RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA (RDEB) KERATINOCYTES SYNTHESIZE TYPE-VII (ANCHORING FIBRIL) COLLAGEN ALPHA-CHAINS OF NORMAL MOLECULAR-SIZE. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 100(4), 515.

Role of imaging in low grade cutaneous B-cell lymphoma presenting in the skin.
Kheterpal, M. K., Dai, J., Geller, S., Pulitzer, M., Ni, A., Myskowski, P. L., … Horwitz, S. M. (2019). Role of imaging in low grade cutaneous B-cell lymphoma presenting in the skin. Journal of the American Academy of Dermatology.

The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: are we there yet?
Geller, S., Myskowski, P. L., Kim, Y. H., Moskowitz, A., & Horwitz, S. (2018). The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: are we there yet? The British Journal of Dermatology, 178(2), 571.

Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and Sezary syndrome.
Jothishankar, B., Almazan, T., Kim, Y., Liauw, S., Smith, S., Kline, J., & Abdulla, F. (2019). Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and Sezary syndrome. British Journal of Haematology.

Lymph node involvement by mycosis fungoides and Sézary syndrome mimicking angioimmunoblastic T-cell lymphoma.
LeBlanc, R. E., Lefterova, M. I., Suarez, C. J., Tavallaee, M., Kim, Y. H., Schrijver, I., … Gratzinger, D. (2015). Lymph node involvement by mycosis fungoides and Sézary syndrome mimicking angioimmunoblastic T-cell lymphoma. Human Pathology, 46(9), 1382–9.

Utility of CD30, Ki-67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation
Raghavan, S. S., Hong, E. K., Kim, Y. H., & Kim, J. (2019). Utility of CD30, Ki-67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation. JOURNAL OF CUTANEOUS PATHOLOGY, 46(1), 33–43.

Low-dose Total Skin Electron Beam Therapy for Refractory Cutaneous CD30 Positive Lymphoproliferative Disorders.
Panjwani, N., Yoo, C. H., Wang, E., Khodadoust, M. S., Kim, Y. H., Hoppe, R. T., & Hiniker, S. M. (2019). Low-dose Total Skin Electron Beam Therapy for Refractory Cutaneous CD30 Positive Lymphoproliferative Disorders. The Journal of Dermatological Treatment, 1–5.

TNFR2-targeted elimination of Tregs and tumor-residing T cells in advanced cutaneous T cell lymphoma
Faustman, D. L., Torrey, H., Khodadoust, M., Defusco, A., Baum, D., Rahbar, Z., & Kim, Y. H. (2018). TNFR2-targeted elimination of Tregs and tumor-residing T cells in advanced cutaneous T cell lymphoma. CANCER RESEARCH, 78(13).

IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.
Bagot, M., Porcu, P., Marie-Cardine, A., Battistella, M., William, B. M., Vermeer, M., … Kim, Y. H. (2019). IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. The Lancet. Oncology.

Volumetric Modulated Arc Therapy and 3-Dimensional Printed Bolus in the Treatment of Refractory Primary Cutaneous Gamma Delta Lymphoma of the Bilateral Legs
Obeid, J.-P., Gutkin, P. M., Lewis, J., Skinner, L., Wang, E. B., Khodadoust, M. S., … Hiniker, S. M. (2019). Volumetric Modulated Arc Therapy and 3-Dimensional Printed Bolus in the Treatment of Refractory Primary Cutaneous Gamma Delta Lymphoma of the Bilateral Legs. PRACTICAL RADIATION ONCOLOGY, 9(4), 220–25.

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
Kim, Y. H., Bagot, M., Pinter-Brown, L., Rook, A. H., Porcu, P., Horwitz, S. M., … Duvic, M. (2018). Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. LANCET ONCOLOGY, 19(9), 1192–1204.

Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sezary Syndrome
Dai, J., Almazan, T. H., Hong, E. K., Khodadoust, M. S., Arai, S., Weng, W.-K., & Kim, Y. H. (2018). Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sezary Syndrome. JAMA DERMATOLOGY, 154(6), 728–30.

A phase 2 randomized study of SHAPE Gel (SHP-141) in patients with early-stage cutaneous T-cell lymphoma: Interim results.
Duvic, M., Kim, Y. H., LeBoeuf, N. R., Porcu, P., Hastings, J., Bassuner, J., … Guitart, J. (2016). A phase 2 randomized study of SHAPE Gel (SHP-141) in patients with early-stage cutaneous T-cell lymphoma: Interim results. JOURNAL OF CLINICAL ONCOLOGY, 34(15).

First-in-human, open label, multicenter phase I of IPH4102, first-in-class humanized anti-KIR3DL2 monoclonal antibody, in relapsed/refractory cutaneous T-cell lymphomas.
Bagot, M., Duvic, M., Vermeer, M., Porcu, P., Whittaker, S., Ram-Wolff, C., … Kim, Y. H. (2016). First-in-human, open label, multicenter phase I of IPH4102, first-in-class humanized anti-KIR3DL2 monoclonal antibody, in relapsed/refractory cutaneous T-cell lymphomas. JOURNAL OF CLINICAL ONCOLOGY, 34(15).

Time to Next Treatment in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL) Receiving Mogamulizumab or Vorinostat: A MAVORIC Post-Hoc Analysis
Sokol, L., Kim, Y. H., Ortiz-Romero, P. L., Pro, B., Scarisbrick, J., Musiek, A., … Bagot, M. (2019). Time to Next Treatment in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL) Receiving Mogamulizumab or Vorinostat: A MAVORIC Post-Hoc Analysis. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 19, S361.

Angiodestructive lymphomatoid papulosis lasting more than 45years.
Lee, G. H., Bae, G. H., Rieger, K. E., Kim, Y. H., & Chiou, A. S. (2019). Angiodestructive lymphomatoid papulosis lasting more than 45years. JAAD Case Reports, 5(9), 767–69.

Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.
Khodadoust, M. S., Rook, A. H., Porcu, P., Foss, F., Moskowitz, A. J., Shustov, A., … Kim, Y. H. (2019). Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1901056.

Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin
Kheterpal, M. K., Dai, J., Geller, S., Pulitzer, M., Ni, A., Myskowski, P. L., … Horwitz, S. M. (2019). Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 81(4), 970–76.

Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas.
Jagadeesh, D., Horwitz, S. M., Bartlett, N. L., Advani, R. H., Jacobsen, E. D., Duvic, M., … Kim, Y. H. (2019). Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas. JOURNAL OF CLINICAL ONCOLOGY, 37(15).

Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or vorinostat: A MAVORIC post-hoc analysis.
Pro, B., Kim, Y. H., Ortiz-Romero, P. L., Sokol, L., Scarisbrick, J., Musiek, A., … Bagot, M. (2019). Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or vorinostat: A MAVORIC post-hoc analysis. JOURNAL OF CLINICAL ONCOLOGY, 37(15).

High-throughput Sequencing of Subcutaneous Panniculitis-like T-Cell Lymphoma Reveals Candidate Pathogenic Mutations.
Fernandez-Pol, S., Costa, H. A., Steiner, D. F., Ma, L., Merker, J. D., Kim, Y. H., … Kim, J. High-throughput Sequencing of Subcutaneous Panniculitis-like T-Cell Lymphoma Reveals Candidate Pathogenic Mutations. Applied Immunohistochemistry & Molecular Morphology : AIMM, 27(10), 740–48.

Antagonism of TNFR2: Focus on novel antibodies with preference for tumor microenvironment Tregs and oncogenes expressed on the tumor
Khodadoust, M., Kim, Y., Yang, M., Torrey, H., Tran, L., & Faustman, D. (2019). Antagonism of TNFR2: Focus on novel antibodies with preference for tumor microenvironment Tregs and oncogenes expressed on the tumor. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMC.

Brentuximab vedotin (BV) versus physician's choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study
Scarisbrick, J., Horwitz, S. M., Prince, H. M., Whittaker, S., Duvic, M., Kim, Y. H., … Dummer, R. (2019). Brentuximab vedotin (BV) versus physician's choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.

An international multi-institutional study for the evaluation of folliculotropic mycosis fungoides: results of the Consensus Histopathologic Review
Gru, A. A., Mitteldorf, C., Pulitzer, M., Hodak, E., Scarisbrick, J., Zic, J., … Battistella, M. (2019). An international multi-institutional study for the evaluation of folliculotropic mycosis fungoides: results of the Consensus Histopathologic Review. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.

Treatment of early-phase mycosis fungoides: results from the Prospective Cutaneous Lymphoma International (PROCLIPI) study
Quaglino, P., Scarisbrick, J., Prince, M., Papadavid, E., Hodak, E., Child, F., … Kim, Y. (2019). Treatment of early-phase mycosis fungoides: results from the Prospective Cutaneous Lymphoma International (PROCLIPI) study. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.

Prognostic factors in mycosis fungoides: the PROCLIPI study
Scarisbrick, J., Quaglino, P., Prince, M., Papadavid, E., Hodak, E., Child, F., … Kim, Y. (2019). Prognostic factors in mycosis fungoides: the PROCLIPI study. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.

Folliculotropic mycosis fungoides presents with two distinct clinicopathological presentations: an international virtual study
Hodak, E., Zic, J., Bagot, M., Gru, A. A., Battistella, M., Mitteldorf, C., … Scarisbrick, J. (2019). Folliculotropic mycosis fungoides presents with two distinct clinicopathological presentations: an international virtual study. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.

Defining B2 involvement in Sezary syndrome results from the PROCLIPI study
Hunjan, M., Bagot, M., Guenova, E., Horwitz, S., Quaglino, P., Child, F., … Scarisbrick, J. (2019). Defining B2 involvement in Sezary syndrome results from the PROCLIPI study. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.

A Long-Term Study of Persistent Sézary Syndrome: Evidence for Antigen Shift by Multiparameter Flow Cytometry and Its Significance in Overall Survival.
Hoffmann, J. C., Atwater, S. K., Hong, E., Kumar, J., Khodadoust, M., Kim, Y., & Ohgami, R. S. (2020). A Long-Term Study of Persistent Sézary Syndrome: Evidence for Antigen Shift by Multiparameter Flow Cytometry and Its Significance in Overall Survival. The American Journal of Dermatopathology, 42(6), 389–96.

Primary Cutaneous Lymphomas Version 2.2020 Featured Updates to the NCCN Guidelines
Mehta-Shah, N., Horwitz, S. M., Ansell, S., Ai, W. Z., Barnes, J., Berta, S. K., … Kim, Y. H. (2020). Primary Cutaneous Lymphomas Version 2.2020 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 18(5), 523–36.

Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study.
Dummer, R., Prince, H. M., Whittaker, S., Horwitz, S. M., Kim, Y. H., Scarisbrick, J., … Duvic, M. (2020). Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. European Journal of Cancer (Oxford, England : 1990), 133, 120–30.

Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma.
Campbell, B. A., Scarisbrick, J. J., Kim, Y. H., Wilcox, R. A., McCormack, C., & Prince, H. M. (2020). Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma. Cancers, 12(8).

Safety of Mogamulizumab in Mycosis Fungoides and Sezary Syndrome: Final Results from the Phase 3 MAVORIC Study
Sokol, L., Duvic, M., Musiek, A., Kim, E., Eradat, H., Elmets, C., … Kim, Y. (2020). Safety of Mogamulizumab in Mycosis Fungoides and Sezary Syndrome: Final Results from the Phase 3 MAVORIC Study. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.

Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.
Weng, W.-K. K., Arai, S., Rezvani, A., Johnston, L., Lowsky, R., Miklos, D., … Kim, Y. H. (2020). Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Advances, 4(18), 4474–82.

Histopathologic Characterization of Mogamulizumab-associated Rash.
Wang, J. Y., Hirotsu, K. E., Neal, T. M., Raghavan, S. S., Kwong, B. Y., Khodadoust, M. S., … Rieger, K. E. (2020). Histopathologic Characterization of Mogamulizumab-associated Rash. The American Journal of Surgical Pathology.

Cutaneous T-cell lymphomas with pathogenic somatic mutations and absence of detectable clonal T-cell receptor gene rearrangement: two case reports.
Rojansky, R., Fernandez-Pol, S., Wang, E., Rieger, K. E., Novoa, R. A., Zehnder, J. L., … Brown, R. A. (2020). Cutaneous T-cell lymphomas with pathogenic somatic mutations and absence of detectable clonal T-cell receptor gene rearrangement: two case reports. Diagnostic Pathology, 15(1), 122.

Two Cases With Features of Lymphocyte Variant Hypereosinophilic Syndrome With STAT3 SH2 Domain Mutations.
Fernandez-Pol, S., Petersen, B., Murphy, J.-E., Oak, J. S., Wang, E. B., Rieger, K. E., … Suarez, C. J. (2020). Two Cases With Features of Lymphocyte Variant Hypereosinophilic Syndrome With STAT3 SH2 Domain Mutations. The American Journal of Surgical Pathology.

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Horwitz, S. M., Feldman, T. A., Hess, B. T., Khodadoust, M. S., Kim, Y. H., Munoz, J., … Hamlin, P. A. (2019). A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.

Ph 1 study of MRG-106, an inhibitor of miR-155, in CTCL.
Foss, F. M., Querfeld, C., Kim, Y. H., Pinter-Brown, L. C., William, B. M., Porcu, P., … Williams, J. (2018). Ph 1 study of MRG-106, an inhibitor of miR-155, in CTCL. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021.
Horwitz, S. M., Ansell, S., Ai, W. Z., Barnes, J., Barta, S. K., Clemens, M. W., … Sundar, H. (2020). NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021. Journal of the National Comprehensive Cancer Network : JNCCN, 18(11), 1460–67.

Evaluating the Treatment Patterns of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: By-time Reanalysis of a Randomized Controlled Phase 2 Study.
Geskin, L. J., Kim, E. J., Angello, J. T., & Kim, Y. H. (2020). Evaluating the Treatment Patterns of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: By-time Reanalysis of a Randomized Controlled Phase 2 Study. Clinical Lymphoma, Myeloma & Leukemia.

Dynamics of the Cutaneous T Cell Lymphoma Microenvironment in Patients Treated with Pembrolizumab Revealed By Highly Multiplexed Tissue Imaging
Schuerch, C. M., Phillips, D. J., Bhate, S. S., Barlow, G. L., Fling, S. P., Ramchurren, N., … Nolan, G. P. (2019). Dynamics of the Cutaneous T Cell Lymphoma Microenvironment in Patients Treated with Pembrolizumab Revealed By Highly Multiplexed Tissue Imaging. BLOOD. AMER SOC HEMATOLOGY.

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells
Ng, P. P., Mobasher, M., Yeung, K. S., Hotson, A. N., Hill, C. M., Madriaga, A., … Janc, J. W. (2019). Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells. BLOOD. AMER SOC HEMATOLOGY.

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma
Mobasher, M., Miller, R. A., Janc, J. W., Kwei, L., Buggy, J. J., Luciano, G., … Radeski, D. (2019). A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.

Safety of Mogamulizumab in Mycosis Fungoides and Sezary Syndrome: Final Results from the Phase 3 Mavoric Study
Kim, Y. H., Bagot, M., Zinzani, P. L., Duvic, M., Morris, S., Kim, E., … Sokol, L. (2019). Safety of Mogamulizumab in Mycosis Fungoides and Sezary Syndrome: Final Results from the Phase 3 Mavoric Study. BLOOD. AMER SOC HEMATOLOGY.

Pembrolizumab in mycosis fungoides with PD-L1 structural variants.
Beygi, S., Fernandez-Pol, S., Duran, G., Wang, E. B., Stehr, H., Zehnder, J. L., … Khodadoust, M. S. (2021). Pembrolizumab in mycosis fungoides with PD-L1 structural variants. Blood Advances, 5(3), 771–74.

Cellular neighborhoods predict pembrolizumab response in cutaneous T cell lymphoma
Schurch, C. M., Phillips, D. J., Gutierrez, B. R., Matusiak, M., Bhate, S. S., Barlow, G. L., … Nolan, G. P. (2020). Cellular neighborhoods predict pembrolizumab response in cutaneous T cell lymphoma. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

Low-Dose Total Skin Electron Beam Therapy Combined With Mogamulizumab for Refractory Mycosis Fungoides and Sezary Syndrome.
Fong, S., Hong, E. K., Khodadoust, M. S., Li, S., Hoppe, R. T., Kim, Y. H., & Hiniker, S. M. (2021). Low-Dose Total Skin Electron Beam Therapy Combined With Mogamulizumab for Refractory Mycosis Fungoides and Sezary Syndrome. Advances in Radiation Oncology, 6(3), 100629.

Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
Kim, Y. H., Prince, H. M., Whittaker, S., Horwitz, S. M., Duvic, M., Bechter, O., … Dummer, R. (2021). Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. European Journal of Cancer (Oxford, England : 1990), 148, 411–21.

Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sezary Syndrome.
Hirotsu, K. E., Neal, T. M., Khodadoust, M. S., Wang, J. Y., Rieger, K. E., Strelo, J., … Kwong, B. Y. (2021). Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sezary Syndrome. JAMA Dermatology.

Radiation Therapy for Primary Cutaneous Gamma Delta Lymphoma Prior to Stem Cell Transplantation.
Wu, Y. F., Skinner, L., Lewis, J., Khodadoust, M. S., Kim, Y. H., Kwong, B. Y., … Hiniker, S. M. (2021). Radiation Therapy for Primary Cutaneous Gamma Delta Lymphoma Prior to Stem Cell Transplantation. Cancer Investigation, 1–11.

Technical report: 3D-printed patient-specific scalp shield for hair preservation in total skin electron beam therapy.
Rahimy, E., Skinner, L., Kim, Y. H., & Hoppe, R. T. (2021). Technical report: 3D-printed patient-specific scalp shield for hair preservation in total skin electron beam therapy. Technical Innovations & Patient Support in Radiation Oncology, 18, 12–15.

Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the Tumor Microenvironment by CODEX Tissue Imaging
Phillips, D., Schuerch, C. M., Khodadoust, M. S., Kim, Y. H., Nolan, G. P., & Jiang, S. (2021). Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the Tumor Microenvironment by CODEX Tissue Imaging. FRONTIERS IN IMMUNOLOGY, 12, 687673.

Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.
Horwitz, S., Zinzani, P. L., Bagot, M., Kim, Y. H., Moskowitz, A. J., Porcu, P., … Scarisbrick, J. (2021). Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial. Leukemia & Lymphoma, 1–10.

Use of chlormethine 0.04% gel for mycosis fungoides after treatment with topical chlormethine 0.02% gel: a phase 2 extension study.
Querfeld, C., Kim, Y. H., Guitart, J., Scarisbrick, J., & Quaglino, P. (2021). Use of chlormethine 0.04% gel for mycosis fungoides after treatment with topical chlormethine 0.02% gel: a phase 2 extension study. Journal of the American Academy of Dermatology.

Cutaneous T cell lymphoma.
Dummer, R., Vermeer, M. H., Scarisbrick, J. J., Kim, Y. H., Stonesifer, C., Tensen, C. P., … Ramelyte, E. (2021). Cutaneous T cell lymphoma. Nature Reviews. Disease Primers, 7(1), 61.

Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.
Horwitz, S. M., Scarisbrick, J. J., Dummer, R., Whittaker, S., Duvic, M., Kim, Y. H., … Prince, H. M. (2021). Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Advances.

Next generation sequencing confirms T-cell clonality in a subset of pediatric pityriasis lichenoides.
Raghavan, S. S., Wang, J. Y., Gru, A. A., Marqueling, A. L., Teng, J. M., Brown, R. A., … Rieger, K. E. (2021). Next generation sequencing confirms T-cell clonality in a subset of pediatric pityriasis lichenoides. Journal of Cutaneous Pathology.

Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study.
Kim, Y. H., Khodadoust, M., de Masson, A., Moins-Teisserenc, H., Ito, T., Dwyer, K., … Bagot, M. (2021). Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study. European Journal of Cancer (Oxford, England : 1990), 156 Suppl 1, S48–S49.

Characterization and outcomes in patients with mogamulizumab-associated skin reactions in the MAVORIC trial.
Musiek, A. C., Whittaker, S., Horowitz, S. M., Bagot, M., Huen, A., Fisher, D. C., … Kim, Y. H. (2021). Characterization and outcomes in patients with mogamulizumab-associated skin reactions in the MAVORIC trial. European Journal of Cancer (Oxford, England : 1990), 156 Suppl 1, S46.

Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC.
Olsen, E. A., Whittaker, S., Willemze, R., Pinter-Brown, L., Foss, F. M., Geskin, L. J., … Scarisbrick, J. J. (2021). Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC. Blood.

Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma.
Phillips, D., Matusiak, M., Gutierrez, B. R., Bhate, S. S., Barlow, G. L., Jiang, S., … Nolan, G. P. (2021). Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma. Nature Communications, 12(1), 6726.

Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management.
Musiek, A. C., Rieger, K. E., Bagot, M., Choi, J. N., Fisher, D. C., Guitart, J., … Kim, Y. H. (2021). Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management. Dermatology and Therapy.

Two Cases of Mycosis Fungoides With PCM1-JAK2 Fusion
Fernandez-Pol, S., Neishaboori, N., Chapman, C. M., Khodadoust, M. S., Kim, Y. H., Rieger, K. E., & Suarez, C. J. (2021). Two Cases of Mycosis Fungoides With PCM1-JAK2 Fusion. JCO PRECISION ONCOLOGY, 5, 646–652.

Prognostic factors in mycosis fungoides and Sezary syndrome: results from the PROCLIPI study
Scarisbrick, J. J., & Kim, Y. H. (2021). Prognostic factors in mycosis fungoides and Sezary syndrome: results from the PROCLIPI study. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.

Mechanisms of resistance to anti-CCR4 antibody, mogamulizumab, in cutaneous T cell lymphoma
Beygi, S., Fernandez-Pol, S., Duran, G., Wang, E. B., Kim, Y., & Khodadoust, M. (2021). Mechanisms of resistance to anti-CCR4 antibody, mogamulizumab, in cutaneous T cell lymphoma. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.

Time-to-next-treatment and time-to-next-systemic treatment in patients included in the PROCLIPI registry
Quaglino, P., Ortiz-Romero, P., Bagot, M., Cozzio, A., Evison, F., Geskin, L., … Scarisbrick, J. J. (2021). Time-to-next-treatment and time-to-next-systemic treatment in patients included in the PROCLIPI registry. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.

Lacutamab in patients (pts) with advanced mycosis fungoides (MF) according to KIR3DL2 expression: early results from the TELLOMAK phase 2 trial
Bagot, M., Kim, Y., Zinzani, P. L., Dalle, S., Beylot-Barry, M., Ortiz-Romero, P. L., … Porcu, P. (2021). Lacutamab in patients (pts) with advanced mycosis fungoides (MF) according to KIR3DL2 expression: early results from the TELLOMAK phase 2 trial. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.

Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study
Kim, Y. H., Khodadoust, M., de Masson, A., Moins-Teisserenc, H., Ito, T., Dwyer, K., … Bagot, M. (2021). Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.

Characterization and outcomes in patients with mogamulizumab-associated skin reactions in the MAVORIC trial
Musiek, A. C. M., Whittaker, S., Horowitz, S. M., Bagot, M., Huen, A., Fisher, D. C., … Kim, Y. H. (2021). Characterization and outcomes in patients with mogamulizumab-associated skin reactions in the MAVORIC trial. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.

What factors guide treatment selection in mycosis fungoides and Sezary syndrome?
Kim, Y. H. (2021). What factors guide treatment selection in mycosis fungoides and Sezary syndrome? Hematology. American Society of Hematology. Education Program, 2021(1), 303–312.

Two Cases of Mycosis Fungoides With PCM1-JAK2 Fusion.
Fernandez-Pol, S., Neishaboori, N., Chapman, C. M., Khodadoust, M. S., Kim, Y. H., Rieger, K. E., & Suarez, C. J. (2021). Two Cases of Mycosis Fungoides With PCM1-JAK2 Fusion. JCO Precision Oncology, 5, 646–652.

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Horwitz, S. M., Ansell, S., Ai, W. Z., Barnes, J., Barta, S. K., Brammer, J., … Sundar, H. (2022). T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 20(3), 285–308.

Resistance to mogamulizumab is associated with loss of CCR4 in Cutaneous T-cell Lymphoma.
Beygi, S., Duran, G. E., Fernandez-Pol, S., Rook, A. H., Kim, Y. H., & Khodadoust, M. S. (2022). Resistance to mogamulizumab is associated with loss of CCR4 in Cutaneous T-cell Lymphoma. Blood.

Characterization and Outcomes in Patients with Mogamulizumab-Associated Skin Reactions in the MAVORIC Trial
Musiek, A., Whittaker, S., Horwitz, S., Bagot, M., Huen, A., Fisher, D., … Kim, Y. (2022). Characterization and Outcomes in Patients with Mogamulizumab-Associated Skin Reactions in the MAVORIC Trial. BRITISH JOURNAL OF HAEMATOLOGY. WILEY.

Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data.
Querfeld, C., Scarisbrick, J. J., Assaf, C., Kim, Y. H., Guitart, J., Quaglino, P., & Hodak, E. (2022). Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data. American Journal of Clinical Dermatology.

Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma.
Bagot, M., Dalle, S., Sokol, L., Tsianakas, A., Musiek, A., Ortiz-Romero, P. L., … Kim, Y. H. (2022). Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma. Dermatologic Therapy, e15634.

Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.
Kim, E. J., Mangold, A. R., DeSimone, J. A., Wong, H. K., Seminario-Vidal, L., Guitart, J., … Poligone, B. (2022). Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial. JAMA Dermatology.

Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.
Jagadeesh, D., Horwitz, S., Bartlett, N. L., Kim, Y., Jacobsen, E., Duvic, M., … Advani, R. (2022). Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma. The Oncologist.

Clinical and Pathological Characteristics and Outcomes Among Patients With Subcutaneous Panniculitis-like T-Cell Lymphoma and Related Adipotropic Lymphoproliferative Disorders.
Guitart, J., Mangold, A. R., Martinez-Escala, M. E., Walker, C. J., Comfere, N. I., Pulitzer, M., … Horwitz, S. (2022). Clinical and Pathological Characteristics and Outcomes Among Patients With Subcutaneous Panniculitis-like T-Cell Lymphoma and Related Adipotropic Lymphoproliferative Disorders. JAMA Dermatology.

Incidence Trends of Primary Cutaneous T-Cell Lymphoma in the US From 2000 to 2018: A SEER Population Data Analysis.
Cai, Z. R., Chen, M. L., Weinstock, M. A., Kim, Y. H., Novoa, R. A., & Linos, E. (2022). Incidence Trends of Primary Cutaneous T-Cell Lymphoma in the US From 2000 to 2018: A SEER Population Data Analysis. JAMA Oncology.

Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome.
Su, T., Duran, G. E., Kwang, A. C., Ramchurren, N., Fling, S. P., Kim, Y. H., & Khodadoust, M. S. (2022). Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome. Oncoimmunology, 11(1), 2115197.

Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral TCell Lymphoma
Horwitz, S. M., Feldman, T. A., Ye, J. C., Khodadoust, M. S., Munoz, J., Hamlin, P. A., … Smith, S. M. (2021). Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral TCell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies
Horwitz, S. M., Foran, J. M., Maris, M., Lue, J. K., Sawas, A., Okada, C., … Ansell, S. M. (2021). Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies. BLOOD. AMER SOC HEMATOLOGY.

Integrating Novel Agents into the Treatment of Advanced Mycosis Fungoides and Sézary Syndrome.
Khodadoust, M. S., Mou, E., & Kim, Y. H. (2022). Integrating Novel Agents into the Treatment of Advanced Mycosis Fungoides and Sézary Syndrome. Blood.

Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: An EORTC-CLTG/ISCL survey.
Quaglino, P., Scarisbrick, J., Roccuzzo, G., Abeldano, A., Battistella, M., McCormack, C., … Hodak, E. (2023). Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: An EORTC-CLTG/ISCL survey. Journal of the European Academy of Dermatology and Venereology : JEADV.

Progression of Mycosis Fungoides After Fingolimod Treatment for Multiple Sclerosis and Targeted Next-Generation Sequencing Demonstrating Potential Links Between the Two Diseases.
Narala, S., Che, Y., Saleem, A., Lock, C. B., Kim, Y. H., & Rieger, K. E. (2023). Progression of Mycosis Fungoides After Fingolimod Treatment for Multiple Sclerosis and Targeted Next-Generation Sequencing Demonstrating Potential Links Between the Two Diseases. JCO Precision Oncology, 7, e2200501.

Minimal/measurable residual disease (MRD) monitoring in patients with lymphoid neoplasms by high-throughput sequencing of the T-cell receptor.
Tung, J. K., Jangam, D., Ho, C. C., Fung, E., Khodadoust, M. S., Kim, Y. H., … Zhang, B. M. (2023). Minimal/measurable residual disease (MRD) monitoring in patients with lymphoid neoplasms by high-throughput sequencing of the T-cell receptor. The Journal of Molecular Diagnostics : JMD.

Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial
Bagot, M., Kim, Y. H., Ortiz-Romero, P. L., Zinzani, P. L., Mehta-Shah, N., Dereure, O., … Porcu, P. (2022). Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial. BLOOD. AMER SOC HEMATOLOGY.

Clinical Characteristics, Treatment Patterns, and Outcomes of Cytotoxic Cutaneous T-Cell Lymphomas
Mou, E., Fernandez-Pol, S., Li, S., Kim, Y. H., & Khodadoust, M. S. (2022). Clinical Characteristics, Treatment Patterns, and Outcomes of Cytotoxic Cutaneous T-Cell Lymphomas. BLOOD. AMER SOC HEMATOLOGY.

Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302
Foss, F. M., Kim, Y. H., Prince, H. M. M., Kuzel, T. M., Yannakou, C. K., Ooi, C. E., … Duvic, M. (2022). Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302. BLOOD. AMER SOC HEMATOLOGY.

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas
Song, Y., Ding, N., Yoon, D. H., Reneau, J. C., Wilcox, R. A., Kim, W. S., … Miller, R. A. (2022). ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas. BLOOD. AMER SOC HEMATOLOGY.

Correlation of sTNFR2 elevation and disease progression in cutaneous T cell lymphomas
Lee, A., Kim, Y., Khodadoust, M., & Faustman, D. L. (2022). Correlation of sTNFR2 elevation and disease progression in cutaneous T cell lymphomas. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

Identification and confirmation via in situ hybridization of Merkel cell polyomavirus in rare cases of posttransplant cutaneous T-cell lymphoma.
Lawrence, L., Wang, A., Charville, G., Liu, C. L., Garofalo, A., Alizadeh, A., … Stehr, H. (2023). Identification and confirmation via in situ hybridization of Merkel cell polyomavirus in rare cases of posttransplant cutaneous T-cell lymphoma. Journal of Cutaneous Pathology.

Identifying and addressing unmet clinical needs in primary cutaneous B-cell lymphoma: A consensus-based paper from an ad-hoc international panel.
Quaglino, P., Pimpinelli, N., Zinzani, P. L., Paulli, M., Pileri, S., Berti, E., … Barosi, G. (2023). Identifying and addressing unmet clinical needs in primary cutaneous B-cell lymphoma: A consensus-based paper from an ad-hoc international panel. Hematological Oncology.

Elucidating genetic factors of cutaneous T-cell lymphoma staging and disease severity through machine learning
Schreidah, C. M., Reynolds, G. B., Shen, H., Fahmy, L. M., Choi, J., Duvic, M., … Geskin, L. J. (2023). Elucidating genetic factors of cutaneous T-cell lymphoma staging and disease severity through machine learning. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.

ISCL/USCLC/EORTC guidelines for the diagnosis, staging, and treatment of pediatric mycosis fungoides
Hodak, E., Amitay-Laish, I., Bagot, M., Battistella, M., Cozzio, A., Duvic, M., … Assaf, C. (2023). ISCL/USCLC/EORTC guidelines for the diagnosis, staging, and treatment of pediatric mycosis fungoides. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.

Health-related quality of life (HRQL) in cutaneous T-cell lymphoma: burden of disease and patient characteristics from a post-hoc analysis of a phase 3 trial in mycosis fungoides and Sezary syndrome
Romero, P., Nixon, A., Kim, Y. H., Molloy, K., Quaglino, P., Scarisbrick, J., … Shinohara, M. (2023). Health-related quality of life (HRQL) in cutaneous T-cell lymphoma: burden of disease and patient characteristics from a post-hoc analysis of a phase 3 trial in mycosis fungoides and Sezary syndrome. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.

Lacutamab in patients with mycosis fungoides: efficacy results according to updated lymph node classification in the TELLOMAK study
Bagot, M., Kim, Y. H., Ortiz-Romero, P. L., Zinzani, P. L., Beylot-Barry, M., Dalle, S., … Porcu, P. (2023). Lacutamab in patients with mycosis fungoides: efficacy results according to updated lymph node classification in the TELLOMAK study. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.

Blood tumour burden does not correlate with skin tumour burden in early-stage mycosis fungoides (MF): PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) registry analysis
Charalambides, M., Evison, F., Kim, Y. H., & Scarisbrick, J. (2023). Blood tumour burden does not correlate with skin tumour burden in early-stage mycosis fungoides (MF): PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) registry analysis. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.

What we have learnt about the treatment of advanced stage MF from the PROCLIPI study
Kim, Y. H., Quaglino, P., & Scarisbrick, J. (2023). What we have learnt about the treatment of advanced stage MF from the PROCLIPI study. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.

Prognostic factors in mycosis fungoides and Sezary syndrome: results from the PROCLIPI study
Scarisbrick, J., Evison, F., & Kim, Y. H. (2023). Prognostic factors in mycosis fungoides and Sezary syndrome: results from the PROCLIPI study. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.

Genomic abnormalities involving class I HLA are common in advanced cutaneous T-cell lymphoma
Kwang, A., Duran, G., Fernandez-Pol, S., Li, S., Najidh, S., Torres, A. B., … Khodadoust, M. (2023). Genomic abnormalities involving class I HLA are common in advanced cutaneous T-cell lymphoma. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.

Two cases of mycosis fungoides with large cell transformation with KMT2A rearrangements
Wadsworth, P. A., Lawrence, L., Suarez, C. J., Saleem, A., Khodadoust, M. S., Kim, Y. H., … Fernandez-Pol, S. (2023). Two cases of mycosis fungoides with large cell transformation with KMT2A rearrangements. JOURNAL OF HEMATOPATHOLOGY.

Primary Cutaneous CD30+Large T Cell Lymphoproliferative Disorder Associated With Prolonged Exposure to Fingolimod
Cooper, J., Soneji, D., Rieger, K., Narala, S., & Kim, Y. (2023). Primary Cutaneous CD30+Large T Cell Lymphoproliferative Disorder Associated With Prolonged Exposure to Fingolimod. MULTIPLE SCLEROSIS JOURNAL. SAGE PUBLICATIONS LTD.

Two cases of mycosis fungoides with large cell transformation with KMT2A rearrangements.
Wadsworth, P. A., Lawrence, L., Suarez, C. J., Saleem, A., Khodadoust, M. S., Kim, Y. H., … Fernandez-Pol, S. (2023). Two cases of mycosis fungoides with large cell transformation with KMT2A rearrangements. Journal of Hematopathology, 16(4), 227–234.

Clinical characteristics, treatment patterns, and outcomes of cytotoxic cutaneous T-cell lymphomas.
Mou, E., Fernandez-Pol, S., Li, S., Rieger, K. E., Novoa, R., Suarez, C. J., … Khodadoust, M. S. (2024). Clinical characteristics, treatment patterns, and outcomes of cytotoxic cutaneous T-cell lymphomas. American Journal of Hematology.

Lacutamab in Patients with Relapsed and Refractory Sezary Syndrome: Results from the Tellomak Phase 2 Trial
Bagot, M., Kim, Y. H., Geskin, L. J., Ortiz-Romero, P. L., Kim, E., Mehta-Shah, N., … Porcu, P. (2023). Lacutamab in Patients with Relapsed and Refractory Sezary Syndrome: Results from the Tellomak Phase 2 Trial. BLOOD. AMER SOC HEMATOLOGY.

Health-Related Quality of Life (HRQL) in Cutaneous T-Cell Lymphoma: A Post Hoc Analysis Examining Disease Burden and Patient Characteristics from the Phase 3 Mavoric Trial in Mycosis Fungoides and Sezary Syndrome
Shinohara, M. M., Kim, Y. H., Molloy, K., Quaglino, P., Scarisbrick, J., Thornton, S. R., … Ortiz-Romero, P. L. (2023). Health-Related Quality of Life (HRQL) in Cutaneous T-Cell Lymphoma: A Post Hoc Analysis Examining Disease Burden and Patient Characteristics from the Phase 3 Mavoric Trial in Mycosis Fungoides and Sezary Syndrome. BLOOD. AMER SOC HEMATOLOGY.

Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration By Balancing Efficacy and Tolerability
Munayirji, B., Khan, N., Myskowski, P., Geller, S., Noor, S., Kheterpal, M. K., … Moskowitz, A. (2023). Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration By Balancing Efficacy and Tolerability. BLOOD. AMER SOC HEMATOLOGY.

Machine Learning-Based Survival Analysis Reveals Prognostic Clinical and Genetic Insights for Patients with Cutaneous T-Cell Lymphoma
Schreidah, C. M., DeStephano, D. M., Pan, S. S., Wang, S., Shen, H., Ta, C. N., … Geskin, L. J. (2023). Machine Learning-Based Survival Analysis Reveals Prognostic Clinical and Genetic Insights for Patients with Cutaneous T-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.